

STATE OF SOUTH CAROLINA
COUNTY OF YORK

State of South Carolina,

vs.

Zachary East Elias,

Defendant.

IN THE COURT OF GENERAL SESSIONS
FOR THE SIXTEENTH JUDICIAL CIRCUIT

Warrant Nos.: 2024A4620302560 – 2564

**MEMORANDUM IN SUPPORT OF
MOTION TO SET BOND**

TO: THE HONORABLE WILLIAM MCKINNON:

On June 24, 2025, Defendant Zachary East Elias, through his undersigned attorneys, submitted a Motion to Set Bond and requested a hearing. The Solicitor's Office, in coordination with the Clerk of Court, set this matter for a hearing on September 15, 2025 at 10:00AM. In advance of this hearing, Mr. Elias now offers this memorandum in support of his Motion to Set Bond in this case:

INTRODUCTION

Zachary Elias is a 29-year-old man with no prior criminal history, no substance abuse or mental health issues, and deep family and community ties. The presumption under South Carolina law is that defendants are entitled to bond absent a clear showing that they pose a danger to the community or a risk of flight. Here, the tragic events underlying this case arose not from criminal intent, but from involuntary intoxication induced by a mislabeled and deceptively marketed products sold as legal substances by the Budiman Smoke Shop. Zach poses no danger outside of those extraordinary and unforeseeable circumstances, and conditions of bond can fully ensure community safety and court appearance.

2025 SEP 11 AM 10:54

CERTIFIED TRUE COPY

ANDREW BRANT
CLERK OF COURT
YORK COUNTY, SC

STATEMENT OF FACTS

The allegations in this case are that in the afternoon of December 4, 2024, Zach legally purchased two “Silly Farms Wavy Wafer” chocolate bars from Budiman Smoke Shop in Rock Hill, South Carolina. The bars were marketed as containing only lawful mushroom derivatives and explicitly promoted as a CBD-style legal alternative. Zach consumed the products in reliance on these representations.

Subsequent testing by the South Carolina Law Enforcement Division (SLED) revealed that the chocolate bars in fact contained *psilocin*, an illegal, dangerous Schedule I controlled substance.¹ Unaware of this, Zach involuntarily ingested the substance and suffered acute drug-induced psychosis. It is alleged that while in this psychotic state, he returned to the smoke shop and discharged a firearm, tragically injuring one individual and fatally wounding two others. The South Carolina State Law Enforcement Division (SLED) tested a sample of Zach’s blood from the evening of the shooting. The results of SLED’s testing confirmed the presence of illegal psilocin as a result of consuming the legally-purchased chocolate.²

Zach has no criminal record, no history of violence, and no history of substance abuse or mental illness. He is supported by a close, upstanding and responsible family, who are willing to post bond and ensure compliance with any conditions set by this Court.

Zach’s alleged actions were not the product of malice, planning, or criminal disposition, but rather the direct and involuntary effect of ingesting a mislabeled, illegal product.

¹ See attached Exhibit 1 – SLED Laboratory results (Silly Farms Wavy Wafer chocolate bars)

² See attached Exhibit 2 – SLED Laboratory results (Blood sample of Zachary Elias)

LEGAL STANDARD

Under South Carolina law, the issue of bond in a criminal case is governed by S.C. Const. Art. I, § 15 and S.C. Code Ann. § 17-15-10.

Section 17-15-10 provides:

“A person charged with a noncapital offense triable in either the magistrates, county or circuit court, shall, at his appearance before any of such courts, be ordered released pending trial on his own recognizance without surety in an amount specified by the court, unless the court determines in its discretion that such a release will not reasonably assure the appearance of the person as required, or unreasonable danger to the community or an individual will result. If such a determination is made by the court, it may impose any one or more of the following conditions of release:

- (1) require the execution of an appearance bond in a specified amount with good and sufficient surety or sureties approved by the court;
- (2) place the person in custody of a designated person or organization agreeing to supervise him;
- (3) place restrictions on the travel, association, or place of abode of the person during the period of release;
- (4) impose any other conditions deemed reasonably necessary to assure appearance as required, including a condition that the person return to custody after specified hours.”

In making a determination about whether a bond is appropriate, courts should consider the totality of circumstances, including the nature of the charges, the weight of the evidence, the defendant’s character, prior record, community ties, and whether the defendant poses a flight risk or danger to the community.

ARGUMENT

I. Zachary Elias Poses No Danger to the Community Absent the Extraordinary Circumstance of Involuntary Intoxication

The State will likely argue dangerousness based on the charged conduct. However, this Court must evaluate dangerousness in context. Zach's actions were not the product of volition, criminal intent, or flawed character. Rather, the evidence shows that the ingestion of mislabeled chocolate bars caused an involuntary, drug-induced psychosis. **But for the deceptive sale of these illegal products, this tragedy would not have occurred.** Zach's lifelong record of law-abiding behavior, his lack of any substance abuse history, and his stable family and community support establish that outside the extraordinary circumstance of involuntary intoxication, he is not a danger to others.

II. Expert Testimony Confirms Zach's Lack of Volition

The defense will present expert testimony from Dr. Daniel Buffington, a nationally recognized clinical pharmacologist with more than three decades of professional and academic experience.³ Dr. Buffington reviewed the toxicological evidence and concluded that ingestion of the chocolate bars containing psilocybin directly caused Zach's acute drug-induced psychosis. Dr. Buffington's findings confirm that Zach's conduct was the product of involuntary intoxication, not criminal intent or predisposition.⁴ Dr. Buffington will testify that this psychosis rendered Zach incapable of understanding or controlling his actions. In his opinion, the behavior was not the product of criminal volition but rather an involuntary pharmacological reaction to hidden psilocybin.

This testimony is critical to the determination of whether Zach poses any ongoing risk, which is highly relevant to the issue of bond. It shows that the charged conduct arose

³ See attached Exhibit 3 – Curriculum Vitae for Dr. Daniel Buffington

⁴ See attached Exhibit 4 – Preliminary report of Dr. Daniel Buffington

from a unique, isolated, and externally triggered episode that is not likely to recur. Zach therefore presents no ongoing danger to the community.

III. Zachary Elias Is Not a Flight Risk

Zach comes from a supportive, stable family with deep roots in South Carolina. His family is prepared to post bond and to ensure his compliance with all conditions of release. Zach has no prior record, no history of absconding, and a defensible case.

Acknowledging that there is absolutely no justification for the arbitrary taking of human life, Zach has a legally defensible case which he looks forward to presenting at the appropriate time. In other words, he has every incentive to appear in court to answer these charges and poses no realistic risk of flight.

IV. Appropriate Bond Conditions Can Ensure Safety and Compliance

Should the Court find any residual concern, reasonable conditions can fully safeguard the community, including:

- Electronic GPS monitoring and home confinement;
- Continued evaluation and monitoring by a licensed mental health provider,
- Residence with and supervision by family members, and
- Any other condition the Court deems necessary.

These conditions will ensure that Zach remains under close supervision and that the community remains protected.

CONCLUSION

This Court is required to balance Zach's rights with legitimate concerns about community safety and flight risk. Here, while the seriousness of the allegations and the

reality of the tragedy to the victims and their families is obvious, Zach's spotless record, strong family support, and the unique pharmacological explanation for his conduct establish that he is neither a danger to the community nor a flight risk. With appropriate conditions, a surety bond will fully secure Zach's appearance in court and safeguard the community.

For these reasons, Zachary Elias respectfully requests that this Court set a reasonable surety bond with conditions as outlined above.

Respectfully submitted,



Alexandra Benevento
STROM LAW FIRM, LLC
6923 N. Trenholm Road, Ste 200
Columbia, South Carolina 29206

Shaun C. Kent
KENT LAW FIRM, LLC
19 S. Mill Street
Manning, South Carolina 29102

Attorneys for Zachary Elias

Columbia, South Carolina
This the 12th day of September, 2025.

Exhibit 1

FITSNENVS

SOUTH CAROLINA LAW ENFORCEMENT DIVISION

FORENSIC SERVICES LABORATORY REPORT

HENRY D. MCMASTER
Governor



MARK A. KEEL
Chief

January 17, 2025

Rebecca Askew
Rock Hill Police Department
120 East Black Street
Rock Hill, SC 29730

DRUG ANALYSIS
SLED LAB: L24-19492
Your Case No: 2412040123
Incident Date: 12/4/2024
[S] Zachary Elias
[V-Deceased] Emad Saadalla
[V-Deceased] Celcei Johnson
[V] Leana Thabet

This is an official report of the South Carolina Law Enforcement Division Forensic Services Laboratory and is to be used in connection with an official criminal investigation. These examinations were conducted under your assurance that no previous examinations of person(s) or evidence submitted in this case have been or will be conducted by any other laboratory or agency.

Mark A. Keel, Chief
South Carolina Law Enforcement Division

ITEMS OF EVIDENCE:

Heat sealed pouch

Item: 4 Zip lock bag containing chocolate bar.
RESULTS:
Psilocin (C-I) found in the sample tested; 1 tested.

Item: 31 "Silly Farms MAGIC MUSHROOM CHOCOLATE" box with residue.
RESULTS:
No analysis performed.

Item: 32 "Silly Farms MAGIC MUSHROOM CHOCOLATE" box containing plastic bag containing partial chocolate bar.
RESULTS:
Psilocin (C-I) found in the sample tested; 1 tested.



P.O. Box 21398, Columbia, South Carolina 29221-1398 Phone (803) 896-7300 Fax (803) 896-7351

Item: 34 "Purple" vape pen containing wax substance.

RESULTS:

Delta-8-Tetrahydrocannabinol (THC) (C-I) found in the sample tested; 1 tested. No weight obtained.

Delta-9-Tetrahydrocannabinol (THC) found.

Item: 36 "Wavy Wafer" box containing two "Silly Farms MAGIC MUSHROOM CHOCOLATE" boxes each containing plastic bag containing chocolate bar.

RESULTS:

Psilocin (C-I) found in the sample tested; 1 tested.

Item: 37 "Wavy Wafer" box containing ten "Silly Farms MAGIC MUSHROOM CHOCOLATE" boxes each containing plastic bag containing chocolate bar.

RESULTS:

Psilocin (C-I) found in the sample tested; 2 tested.

This report contains the conclusions, opinions and interpretations of the analyst whose signature appears below, and the control schedule for substance(s) listed within the report is based on the date the report was issued.

Technical records supporting the conclusions in this report are available upon request. Afford sufficient time for production.



Shana B. Sorrells
Forensic Scientist



P.O. Box 21398, Columbia, South Carolina 29221-1398 Phone (803) 896-7300 Fax (803) 896-7351

Supplement to Analysis for Controlled Substance

I, Shana Sorrells, am a Forensic Scientist employed by the South Carolina State Law Enforcement Division (SLED), certified by SLED as a Forensic Scientist qualified to perform testing and analysis for controlled and/or dangerous substances prohibited by law in this State by Title 44, Chapter 53 of the Code of Laws and Rule 61-4 of the Department of Health and Environmental Control.

I have 18 years and 9 months experience as a Forensic Scientist. During that period, I have been qualified as an expert witness and testified in court no less than 50 times. I have received the following training as a Forensic Scientist.

B.S. Chemistry, University of South Carolina, 2003

M.S. Analytical Chemistry, University of South Carolina, 2005

South Carolina Law and Legal Training, South Carolina Criminal Justice Academy, 2006

Forensic Scientist, Toxicology Department, South Carolina Law Enforcement Division, 2006-2014

Drug Evaluation and Classification Training, South Carolina Criminal Justice Academy, 2006

Training in Forensic Drug Analysis, South Carolina Law Enforcement Division, 2014

I tested the above item(s) using the following legally reliable forensic laboratory procedures approved by SLED:

☒ Chemical Test

☐ Microscopic Exam

☐ Infrared Spectroscopy

☐ Visual Examination

☒ Gas Chromatography

☒ Mass Spectroscopy

☐ Physical Test

☐ Published Literature

Forensic Scientist



Shana B. Sorrells

Date: January 17, 2025



P.O. Box 21398, Columbia, South Carolina 29221-1398 Phone (803) 896-7300 Fax (803) 896-7351

Exhibit 2

FITSNEN'S

SOUTH CAROLINA LAW ENFORCEMENT DIVISION
FORENSIC SERVICES LABORATORY REPORT

HENRY D. MCMASTER
Governor



MARK A. KEEL
Chief

Rebecca Askew
Rock Hill Police Department
120 East Black Street
Rock Hill, SC 29730

TOXICOLOGY DEPARTMENT

February 06, 2025
SLED No: L24-19492
Your Case No: 2412040123
Incident Date: 12/04/2024

[S] Zachary East Elias
[V-Deceased] Emad Makram
Thabet Saadalla
[V-Deceased] Celcei Neil Johnson
[V] Leana Thabet

This is an official report of the South Carolina Law Enforcement Division Forensic Services Laboratory and is to be used in connection with an official criminal investigation. These examinations were conducted under your assurance that no previous examinations of person(s) or evidence submitted in this case have been or will be conducted by any other laboratory or agency.

Mark A. Keel, Chief
South Carolina Law Enforcement Division

ITEMS OF EVIDENCE

Item: 3 **Sample Type: Blood (Toxicology) - labeled "Zachary Elias"**

Analysis by Headspace Gas Chromatography (GC) and/or Headspace Gas Chromatography/Mass Spectrometry (GC/MS)

| Analyte | Result | Units | Threshold |
|---------|----------|----------|-----------|
| Ethanol | Negative | % (g/dL) | 0.01 |



P.O. Box 21398, Columbia, South Carolina 29221-1398 Phone (803) 896-7300 Fax (803) 896-7351

2/6/25

Screen by Enzyme Linked Immunosorbent Assay (ELISA)

| Analyte | Result | Units | Threshold |
|---------------------------|----------|-------|-----------|
| Amphetamine | Negative | ng/mL | 20.00 |
| Barbiturates | Negative | ng/mL | 100.00 |
| Benzodiazepines I | Negative | ng/mL | 20.00 |
| Benzodiazepines II | Negative | ng/mL | 10.00 |
| Benzodiazepines III | Negative | ng/mL | 10.00 |
| Buprenorphine | Negative | ng/mL | 1.00 |
| Cocaine Metabolite | Negative | ng/mL | 50.00 |
| Dextromethorphan | Negative | ng/mL | 10.00 |
| Fentanyl | Negative | ng/mL | 1.00 |
| Generic Opioids | Negative | ng/mL | 10.00 |
| Meprobamate | Negative | ng/mL | 300.00 |
| Methadone | Negative | ng/mL | 25.00 |
| Methamphetamine | Negative | ng/mL | 20.00 |
| Opiates | Negative | ng/mL | 10.00 |
| Oxycodone I | Negative | ng/mL | 10.00 |
| Oxycodone II | Negative | ng/mL | 10.00 |
| Phencyclidine | Negative | ng/mL | 5.00 |
| Tramadol | Negative | ng/mL | 10.00 |
| Tricyclic Antidepressants | Negative | ng/mL | 60.00 |
| Zolpidem | Negative | ng/mL | 10.00 |

Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)

| Analyte | Result | Units | Threshold |
|---------------------------------------|----------|-------|-----------|
| Tetrahydrocannabinol Synonyms: THC | 11 | ng/mL | 1.00 |
| Psilocin | Positive | | |

Comprehensive Analysis


A comprehensive drug screen utilizing gas chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry was performed on this sample. With the exception of the compound(s) listed, no other drugs or poisons of concern were found.



P.O. Box 21398, Columbia, South Carolina 29221-1398 Phone (803) 896-7300 Fax (803) 896-7351

2/6/25

*This report contains the conclusions, opinions and interpretations of the analyst whose signature appears below.
Technical records supporting the conclusions in this report are available upon request. Afford sufficient time for production.*



Quintus Young II
Forensic Toxicologist

CC: Matt Davis - South Carolina Law Enforcement Division

For any additional interpretation of results please contact the Toxicologist above at the SLED Toxicology Department , (803) 896-7385.

FITSNEWS



P.O. Box 21398, Columbia, South Carolina 29221-1398 Phone (803) 896-7300 Fax (803) 896-7351

Exhibit 3

FITSNENVS

CURRICULUM VITAE

DANIEL E. BUFFINGTON, PharmD, MBA

Clinical Pharmacology Services, Inc.
6285 E. Fowler Ave
Tampa, FL 33617

813-983-1500 Clinic
813-983-1501 Fax
813-679-0792 Cell

PERSONAL:

| | |
|----------------|----------------|
| Place of Birth | Clearwater, FL |
| Citizenship | United States |

EDUCATION:

| | | |
|---------------|---|---------------|
| Postgraduate | Emory University Hospital | |
| | Pharmacy Practice Residency | 07/87 – 06/88 |
| | Clinical Pharmacology Fellowship | 07/88 – 06/89 |
| | Atlanta, GA | |
| | Mercer University, School of Pharmacy | |
| | Doctor of Pharmacy (PharmD) | 08/83 - 06/87 |
| | Atlanta, GA | |
| | Mercer University, College of Business & Economics | |
| | Master of Business Administration (MBA) | 06/87 – 05/95 |
| | Atlanta, GA | |
| Undergraduate | University of South Florida | |
| | Biology | 08/80 – 08/83 |
| | Tampa, FL | |

SPECIALTY TRAINING:

National Association of Drug Diversion Investigators (NADDI)
Southern Regional Training
Certified Drug Diversion Investigator & Training Conference
St. Pete Beach, FL
05/07-08/15 & 05/17/23

Transportation & Management of Hazardous Materials
Certified Transportation & Management of Hazardous Materials
Morton Plant Mease Hospital, Tampa, FL
09/08/01

Nephrology Preceptorship

University of Pittsburgh, School of Pharmacy, Dr. Gary Matzke
Pittsburgh, PA
10/25/95

EMPLOYMENT:

01/07 – Present **American Institute of Pharmaceutical Sciences, Inc.**
President & CEO
Tampa, FL

05/91 – Present **University of South Florida**

College of Medicine
Department of Internal Medicine
Division of Clinical Pharmacology
Clinical Associate Professor of Medicine
Tampa, FL
05/1991 – 2000

College of Pharmacy
Department of Pharmacotherapeutics and Clinical Research
Clinical Associate Professor of Pharmacy
Tampa, FL
2011 - Present

College of Nursing
Clinical Pharmacology for Advanced Registered Nurse
Practitioners
1998 – 2002

01/90 - Present **Clinical Pharmacology Services, Inc.**
President & CEO
Tampa, FL

PRIOR EMPLOYMENT:

03/14 – 2019 **United States Center for Medicare and Medicaid Services (CMS)**
Washington, DC & Baltimore, MD
2014 - 2019

Center for Medicare and Medicaid Innovation (CMMI)
ORISE Fellow – Medication Safety Expert
03/2014 – 10/2016

Center for Clinical Standards and Quality (CCSQ)
Technical Expert - Medication Management and Safety
11/2016 – 01/2019

| | |
|---------------|--|
| 10/13 –07/15 | North Shore Long Island Jewish Health System CareConnect® and LiveWell® Director of Pharmacy Long Island, NY |
| 06/89 - 06/91 | H. Lee Moffitt Cancer Center Gynecology/Oncology, Infectious Diseases, Clinical Research Clinical Pharmacist Tampa, FL |
| 03/89 - 09/90 | Professional Designs, Inc. Presentation Graphics & Design Consulting President & CEO Atlanta, GA |
| 01/85 - 06/89 | Beta Technology Medical Computer Systems and Presentation Consulting President & CEO Atlanta, GA |

LICENSES:

| | |
|--------------------|-------------|
| Florida (Pharmacy) | PS 0024260 |
| Georgia (Pharmacy) | RPH 0150301 |

NATIONAL PROVIDER ID (NPI):

| | |
|--------------------------------|------------|
| Daniel E. Buffington, PharmD | 1285634667 |
| Clinical Pharmacology Services | 1861781338 |

FACULTY AFFILIATIONS:

| | |
|-----------------------------------|--|
| Belmont University | College of Pharmacy Clinical Preceptor Nashville, TN 2018 – Present |
| Creighton University | College of Pharmacy Clinical Preceptor Omaha, NE 2007 – Present |
| Florida A&M University | College of Pharmacy Clinical Preceptor Tampa, FL 1999 – Present |
| Idaho State University | College of Pharmacy Affiliate Faculty Member Pocatello, ID 2004 – Present |

| | |
|---|--|
| Lake Erie College of Osteopathic Medicine | College of Pharmacy Clinical Preceptor Bradenton, FL 2010 – Present |
| Larkin University, College of Pharmacy | College of Pharmacy Adjunct Instructor Miami, FL 2019 – Present |
| Marshall University | School of Pharmacy Adjunct Faculty Huntington, WV 2018 – Present |
| Medical University of South Carolina | College of Pharmacy Clinical Preceptor Charleston, SC 2019 – Present |
| Mercer University | Southern School of Pharmacy Adjunct Faculty, Department of Pharmacy Atlanta, GA 2000 – Present |
| Nova Southeastern University | College of Pharmacy Department of Pharmacy Practice Clinical Assistant Professor of Pharmacy North Miami Beach, FL 1996 – Present |
| Palm Beach Atlantic University | Lloyd L Gregory School of Pharmacy Clinical Instructor of Pharmacy Practice West Palm Beach, FL 2003 – Present |
| Philadelphia College of Osteopathic Medicine | College of Pharmacy Clinical Assistant Professor of Pharmacy Practice Suwanee, GA 2013 – Present |
| Shenandoah University | College of Pharmacy Preceptor Winchester, VA 2004 – Present |
| University of Connecticut | College of Pharmacy Gratis Adjunct Clinical Instructor of Pharmacy Practice Storrs, CT 2014 – Present Guest Professorship 02/2012 – 04/2012 |

| | |
|-------------------------------------|--|
| University of Florida | College of Pharmacy Department of Pharmacy Practice Assistant Clinical Professor & Clinical Preceptor Gainesville, FL 1990 – Present |
| University of Iowa | College of Pharmacy Primary Preceptor and Site Coordinator Iowa City, IA 2019 – Present |
| University of South Carolina | College of Pharmacy Clinical Preceptor Columbia, SC 2018 – Present |
| University of South Florida | College of Pharmacy Clinical Associate Professor of Pharmacy Tampa, FL 2007 – Present |

PROFESSIONAL & COMMUNITY ORGANIZATIONS:

NATIONAL

National Association of Drug Diversion Investigators, 2015 – Present

Healthcare Information and Management Systems Society (HIMSS), 2018 – Present

- Member North American Chapter

National Academies of Practice, 2016 – Present

- Practitioner Fellow

American Pharmaceutical Association (APHA), 1985 – Present

- Government Affairs Committee, 2013 – Present
- Board of Trustees Executive Committee,
 - First Term, 2011 – 2014
 - Second Term, 2016-2019
- Finance Committee, 2016 - 2019
- APHA Delegate, 2011 – Present
- Strategic Directions Committee, 2011 - Present
- STAT Task Force - Reimbursement for Pharmacy Services, 1995, 1996
- Academy of Pharmaceutical Care Specialists, 1996 – Present
- Student APA, Vice-President, 1983 -1985

Board of Pharmacy Specialties, 2009 - 2012

- Oncology Specialty – Exam Question Development
- Pharmacotherapy Specialty – Exam Question Development
- Ambulatory Care Specialty Counsel, 2009 – 2012

American Medical Association (AMA), 2004 – Present

- CPT Editorial Panel Board Member, 2020 to Present
- CPT Editorial Panel – CPT Advisor, Pharmacists, 2015 – 2019
- RUC Emerging Issues Workgroup, 2015 – 2019
- Therapeutic Drug Monitoring Workgroup, 2013 – 2016
- Drug Infusion Workgroup, 2005 – 2009

- Current Procedural Terminology, Editorial Panel, CPT Advisor, 2004 - Present
- Healthcare Professional Advisory Committee, Pharmacy, 2004 - Present

American College of Clinical Pharmacology (ACCP), 1991 - Present

- Program Planning Committee, 1992 - 1994

American College of Clinical Pharmacy (ACCP), 1988 - Present

- Clinical Affairs Committee, 1991 -1992
- Reimbursement Task Force, 1993 -1994
- Public & Professional Relations Committee, 1994 -1995

American Society of Consultant Pharmacists, 1988 – Present

American Society of Health-System Pharmacists (ASHP), 1985 – Present

- Specialty Practice Group (SPG)
- Vice-Chair, 1996 – 1997
- Public Policy and Government Relations Committee, 1995 – 1996
- Section for Clinical Specialist, 1995 - Present
- Vice-Chair, 1993 -1994
- Task Force on Unlabeled Uses of Medications, 1993 - 1994
- House of Delegates, 1993 – present
- Clinical Pharmacokinetics, 1990 -1995

International Society for Pharmacoeconomics and Outcomes Research, 2000 - 2003

American Society of Microbiology (ASM), 1992 – 1997

STATE

American Cancer Society, Hillsborough County, 1991 -1993

- Board of Directors, 1991 - 1993

American College of Clinical Pharmacology, Tampa Chapter, 1989 – Present

- Tampa Chapter, Program Committee, 1991 - 1993

Association for Clinical Research Professionals – SunCoast Chapter, 1999 - 2000

- SunCoast Chapter, President-elect, 1999
- SunCoast Chapter, President, 2000

Florida Society of Health-System Pharmacists, 1989 – Present

- Experiential Education Innovation Forum, 2012
- House of Delegates, 2011 - Present
- Legal and Regulatory Affairs Council Chairman, 1992, 1993 member, 2002-2005
- President, 2000 - 2001
- President Elect, 1999
- Educational Affairs Council, Council Chairman, 1998
- House of Representative, 1993 - present
- Reimbursement Task Force, 1993 - 1995
- Board of Directors, 1993 -1995
- Communications Council/Board Liaison, 1993 – 1994
- Board of Directors, 1992 - Present
- Clinical Council/Chair, 1992 -1993
- Editor, FSHP/Digest, 1990 -1993
- Clinical Council/member, 1990 -1992

Florida Independent Pharmacy Association, 2009 – 2019

Southwest Florida Society of Hospital Pharmacists, 1989 – 2003

- President, 1992 - 1993
- President-Elect, 1991 - 1992
- Nominations Committee 1990 - 1991

Florida Pharmacy Association, 1991 – Present

- Chairman, Board of Directors, 2022 to 2023
- President, 2021- 2022
- President (Interim), 2020-2021
- President-Elect, 2020 to 2021
- Government Affairs Committee, 2012 – 2022
- Professional Affairs Council, 2000 – 2002; 2012-2014
- Public Affairs Committee, 1993
- Public Relations Committee, 1992 -1993

Hillsborough County Pharmacy Association, 1991 - 2010

- Board of Directors, 1992 -1993

Atlanta Academy of Institutional Pharmacist, 1987 -1990

University of South Florida, 1993 – Present

- Taneja College of Pharmacy Advisory Board, 2020 - Present
- USF Institutional Review Board, Human Research, 1994 – 1996
- USF Community Music Division, Board of Directors, 1994 -1996
- Health and Safety Committee, 1993 - 1996

Mercer University School of Pharmacy, 1984 - Present

- Board of Visitors 2019 - Present
- National Deans List, 1986 -1987
- Mercer Dean's List, 1986, 1987
- Class of 1987, Vice-President, 1985 -1987
- Class of 1987, Secretary, 1984 -1985
- Georgia Pharmaceutical Association: Board of Directors/Student Rep, 1984

Florida Pharmacy Foundation, 2012 - 2014

- Board of Trustee, 2012 - 2014

Florida Community Pharmacy Network and Political Action Committee, 2004

COMMUNITY

The Florida Wind Band

- Board of Directors, President, 2022 – Present
- Board of Directors, 2021-2022

LifePath Hospice and Palliative Care, 1999 - 2003

- Executive Committee, 2003
- Bioethics Committee, Chairman, 2001 – 2003
- Board of Directors, Tampa, FL, 1999 – 2003

METRO BAND, Christian Music Ministry, 1994 – 2004

Idlewild Baptist Church, Orchestra, 1989 – Present

Great American Teach-In, 2001 – 2012

- Young Middle Magnet School
- Lewis Elementary School

Hillsborough Regional Science Fair Judge, 2003 and 2001

SideFX: Medical Band (Charity Functions), 1993 – Present

Judeo Christian Health Clinic Volunteer, 1991-1995

Paint Your Heart Out Tampa, Hillsborough County Medical Association, 1989-1991

Community Relations Board, Ex-Officio Member, City of Clearwater, 1979

FRATERNITY - PROFESSIONAL

Kappa Psi Pharmaceutical Society, 1984

Phi Lambda Sigma - Leadership / Honor Society (Mercer University), 1985

- Vice-President, 1986 -1987
- National Convention Representative, 1986

FRATERNITY – SOCIAL

Sigma Alpha Epsilon Fraternity, 1981

PROFESSIONAL APPOINTMENTS AND ENGAGEMENTS:

| | |
|----------|--|
| 10-04-09 | National Dean's Advisory Council University of Florida, College of Pharmacy Gainesville, FL |
| 01-13-09 | Medication Measures Special Study Technical Expert Panel Quality Partners of Rhode Island |
| 06-01-06 | Pharmacy Quality Alliance (PQA) Center for Medicare and Medicaid Services (CMS) Baltimore, MD |
| 12-12-05 | Technical Advisory Panel: Center for Medicare & Medicaid (CMS), Medicare Prescription Drug, Improvement and Modernization Act of 2003 Baltimore, MD (BearingPoint) |
| 04-03-05 | Board of Pharmaceutical Specialties (BPS) Focus Group Pharmacy Certification Programs, Orlando FL |
| 12-18-03 | Health Care Professionals Advisory Committee (HCPAC) American Medical Association, Current Procedural Terminology (CPT) Editorial Panel, 2003 – Present |
| 11-15-02 | Pharmacists Services Technical Advisory Coalition (PSTAC) Representing the American Society of Health-Systems Pharmacists 2002 – Present |
| 11-01-02 | Mercer Southern School of Pharmacy Campaign Committee Associate Chair |
| 10-02-02 | Dean's Advisory Board of Visitors Mercer University, Southern School of Pharmacy, Atlanta, GA |
| 09-23-00 | Dean's National Advisory Board University of Florida, College of Pharmacy, Gainesville, FL |

- 1999 – 2016 **LifePath Hospice & Palliative Care, Board of Directors**
Tampa, FL
- 07-16-99 **National Faculty: Managing Respiratory Tract Infections in the New Millennium**
Thomas Beam, Jr. Memorial Institute, Bayer, Denver, CO

EDITORIAL REVIEW BOARD:

American Journal of Health-System Pharmacy Supplement, Guest Editor, 2007
American Pharmacists Association, Reviewer, 2007
Cancer Control - Journal of the Moffitt Cancer Center
Florida Digest, Co-Editor, 1991, 1992, 1993
Florida Journal of Hospital Pharmacy
Clinical Pharmacy
American Journal of Hospital Pharmacy
Hospital Pharmacy

HONORS / AWARDS / SCHOLARSHIPS:

Pharmacy Practice Leadership Award, 2023
University of South Florida, Health Sciences

Pharmacy Leadership Award, 2022
National Community Pharmacists Association & Florida Pharmacy Association

Preceptor Award, 2018
Palm Beach Atlantic University Gregory School of Pharmacy

Distinguished Service Award, 2016
Florida Society of Health-System Pharmacists

Florida Pharmacist of the Year - James H Beal Award, 2016
Florida Pharmacy Association

**Outstanding Achievement in the Field of Pharmaceutical Relations in Florida
R Q Richards Award, 2015**
Pharmaceutical Public Relations

Outstanding Pharmacy Service Award, 2013
University of Florida, College of Pharmacy

Appreciation for Service, Mock Trial, 2011 - 2018
University of South Florida, College of Pharmacy

APhA Practice Excellence - Daniel B. Smith Award, 2010
American Pharmacists Association

Education Awareness Certificate, 2009
University of South Florida

APhA Pinnacle Award, 2008

American Pharmacists Association Foundation

Award of Excellence, 2008

American Society of Health-System Pharmacists

The Inaugural Distinguished Alumni Award, 2009

Mercer University, College of Pharmacy & Health Sciences

NetSmartz® Sponsorship Award, 2007

Hillsborough County

Dr. G. Van Greene Distinguished Lecturer, 2005

Mercer University College of Pharmacy

Distinguished Achievement Award in Clinical Pharmacotherapeutic Practice, 2005

Academy of Pharmacy Practice and Management

American Pharmacists Association

Burgess Gordon Memorial Award, 2004

American Medical Association

Florida Pharmacist of the Year, 2002

Florida Society of Health-System Pharmacists

Florida Pharmacist Fore Runner Award, 1994

Florida Society of Hospital Pharmacists

President's Award, 1993

Florida Society of Hospital Pharmacists

Distinguished Service Award, 1991 -1993

Florida Pharmacy Association

Outstanding Service Award, 1993

Florida Society of Hospital Pharmacists

Bristol Laboratories Award, 1987

Mercer University, School of Pharmacy

Collegiate Student Government Award, 1987

Mercer University

Outstanding Young Men of America Award, 1987

Mercer University

United States Achievement Academy Award, 1987

Mercer University

Georgia Pharmaceutical Association, 1986

Scholarship

Churches Home Foundation, 1986

Scholarship

Clearwater Community Service Award, 1980

City of Clearwater, FL

PHILANTHROPY:

Florida Woodward Band (2022)
Camp Twin Lakes – Spin for Kids (2022)
Huddle Touch Inc – Team Sponsorship (2022)
Florida Pharmacy Association (2022)
University of South Florida Certificate of Appreciation Anti-Drinking
and Driving Campaign (2020)
International Health Service Collaborative (2017)
APHA Foundation – 1953 Society (2015 – Present)
Children's Hospital (2015 - 2016)
Pediatric Cancer (2014)
Ruth Eckerd Hall (2013 – 2018)
AIM Convention Health Fair (2012)
Autism Speaks (2010 - 2015)
Make A Wish Foundation (2010 - 2012)
Denver & the Mile-High Orchestra - Global Missions Project – Russia (2010)
Temple Terrace Rotary Club – Opening ceremony Linwood Park (2010)
Idlewild Baptist Church - Cuba Missions Trip (2009 – Present)
Steve McCauley Memorial Scholarship Fund Golf Tournament (2009)
Children's Dream Fund (2009)
Temple Terrace Rotary Foundation (2008)
University of South Florida Library Fund (2007 – 2014)
Ohio State University Pharmacy Society (2007 - 2010)
Internet Safety for Kids (NetSmartz® Launch), Hillsborough County, FL (2007)
Cross International (2007)
Global Missions (2006 - 2011)
Stamford University (2006 - 2008)
Breast Cancer Donation (2006)
Cystic Fibrosis Foundation (2006)
University of South Florida Foundation (2005 – Present)
American College of Clinical Pharmacy (2005 - Present)
American Pharmacists Association (2005 – Present)
American Cancer Society (2005 - 2010)
Mercer University (2002 - 2016)
Muscular Dystrophy Association (2002 – 2012)
American Society of Consultant Pharmacists Foundation (2001 – Present)
Kayla's Hope for Kids Golf Tournament (2001 – 2014)
Proceeds benefit The Children's Hospital of Philadelphia, Division of Neuro-Oncology
Florida Family Association (2001 - 2006)

MUSIC PERFORMANCES:

- 06-22-05 **Southern Baptist Convention, Nashville, TN**
Celebration Orchestra, Idlewild Baptist Church
- 03-22-04 **Cuba National Orchestra: Global Missions Project, Havana, Cuba**
National Theatre Performance (03-25-2004)
Concert in the Park, Plaza De Armas (03-26-2004)
- 2003 - Present **Idlewild Baptist Church, Tampa, FL, Celebration Choir and Orchestra**
- 01-29-99 **Academy of Gospel Music Arts**
Orlando Region, Metro Band
- 1993 - Present **SideFX: Medical Band**

POSTER PRESENTATIONS:

- Evaluation of the Utility of Sinus Endoscopy versus Sinus Aspiration for Microbiologic Documentation of Acute Maxillary Sinusitis-Zagam Endoscopy Study Group**
International Conference on Antimicrobial Agents and Chemotherapy 35th (ICAAC)
San Francisco, CA, 09-15-1995
- Development of Reimbursement Mechanisms for Pharmacist Services**
American Pharmacy Association 1995 Annual Meeting
Orlando, FL, 03-19-1995
- Creation of a Software Program to Assess Patient Risk Factors for the Development of Candidemia**
American Society of Hospital Pharmacists, Midyear Clinical Meeting
Miami Beach, FL 12-06-1994
- Task Force on Reimbursement for Cognitive Services Report**
ACCP Annual Meeting
08-15-1993
- Clinical Pharmacokinetics: Software Review**
American Society of Hospital Pharmacists, Clinical Midyear Meeting
Dallas, TX 12-07-1988

ACADEMIC COURSE LECTURES:

University of South Florida, College of Pharmacy
Tampa, FL

Pharmacy Practice Orientation

Medical Informatics and Technology
Interoperability and Health Information Exchanges

Pharmacy Management
Practice & Human Resource Management

Pharmacists' Role in the US Healthcare System

The Future of Pharmacy

Healthcare Administration and Economics

Forensic Pharmacology: Toxicology & Drugs of Abuse

Professional Practice Leadership & Advocacy

USF AMCP Student Group Lecture

University of South Florida, College of Nursing
Tampa, FL

**Clinical Pharmacology for Advanced Nurse Practitioners
(USF, NGR 6199)**
Registered Nurse Practitioners - Graduate Program
Course Director
1998 – 2002

University of South Florida, College of Public Health
Tampa, FL

Pharmacoepidemiology (PHC 6934) – "Pharmacoeconomics"

University of Florida College of Pharmacy
Gainesville, FL

Clinical Pharmacokinetics (PHA 4123, PHA 5121)
Aminoglycosides & Vancomycin Pharmacokinetics: Clinical Applications
BS & Doctor of Pharmacy Programs
Pharmacy Management (PHA 4210)
"Reimbursement for Pharmaceutical Care Services"
BS & Doctor of Pharmacy Programs

Clinical Pharmacy & Therapeutics
Non-Traditional Doctor of Pharmacy Program

Topics:

- Pharmacokinetics
- Gynecologic Malignancies
- Infectious Diseases (Sinusitis, Infectious Diarrhea)
- Allergic Rhinitis

**University of Connecticut - School of Pharmacy Department of Pharmacy
Practice**
Hartford, CT

Creating, financially sustaining, and providing MTM Services
2012

MTM and Pharmacists' Practice Models
2012

Lake Erie College of Medicine
Erie, PA

Toxicology Lecture
2015 - 2016

Forensic Pharmacology
2014

University of Washington
Seattle, WA
2013

Preceptor Development Conference
Ft Myers, FL

Encouraging Critical Thinking Skills in Students and Residents
2013

Nova Southeastern University
Ft Lauderdale, FL

**Strategic Positioning of MTM Services and Reimbursement in HealthCare
Reform**
2012

Philadelphia College of Medicine
Atlanta, GA

Advanced Clinical Pharmacy Practice
2011

University of Pittsburgh, School of Pharmacy
Pittsburgh, PA

Nicholas C. Tucci Lecture
2009

West Virginia University, School of Pharmacy
Morgantown, WV

Annual Bergy Lecture
2011

University of Maryland
Baltimore, MD

Future of Medication Therapy Management: Winning or Losing
2008

Mercer University Southern School of Pharmacy Inaugural Distinguished Lecture
Atlanta, GA

Medicare Modernization Act
Focus on Improving Care
2005

Bernard J. Dunn School of Pharmacy at Shenandoah University
Washington, DC

Hooding Ceremony – Guest Speaker
2018

University of South Florida
Tampa, FL

Interoperability and Health Information Exchange
2018

PUBLICATIONS:

Arnold J, Beatty S, Buffington D, Burns A, Hanson L, Isetts B, Schwartz L, et al.
Relative Value Units (RVUs): A Primer on Why They Are Important to Pharmacists
Pharmacy Health Information Technology Collaborative
April 2022, July 2022

Buffington D, Lozicki A
Summary Chart of Expanded Pharmacy Services – Chapter 7
Ultimate 2022 Florida MPJE Review – Mastering the MPJE Competencies
January 2022

Garrison N, Spector S, Buffington D, Granito K, Zhang H, Talbot G
Sparfloxacin for the treatment of acute bacterial maxillary sinusitis documented by sinus puncture
Annals of Allergy, Asthma & Immunology
January 2000

Buffington D, Lozicki A, Alfieri T, Bond C
Understanding factors that contribute to the disposal of unused opioid medication
Journal of Pain Research
February 2019

Buffington D
Understanding factors that contribute to the disposal of unused opioid medication
Opiate Disposal/Pain Research (Purdue Pharma)
Sep 2018

Brill J, Ashmore J, Brengman M, Buffington D et al
White Paper AGA: An Episode-of-Care Framework for the Management of Obesity:
Moving Towards High Value, High Quality Care
Clinical Gastroenterology and Hepatology the Official Clinical Practice Journal,
Feb 2017

Whalen K, Hardin H, Buffington D
Medication Therapy Management: A Pharmacotherapy and Medication System
Primer, McGraw-Hill, 2017

Green D, Rubenstein A, Buffington D, Flemming R, et al
Leveraging FDA and CMS collaboration to enhance quality improvement in safe
medication use
Research in Social and Administrative Pharmacy, Jul 2016

Isetts B, Buffington D, Carter B, Smith M, Polgreen L, James P
Evaluation of Pharmacists' Work in a Physician-Pharmacist Collaborative Model for the
Management of Hypertension, Pharmacotherapy, Feb 2016

Buffington D, Wager D, McGann P
All In: Using Healthcare Collaboratives to Save Lives and Improve (Care, Spurlock &
Teske), Chapter 4: "Key Elements of Effective Collaborative Design – Fostering
Leadership at All Levels"
2015

Buffington D (Contributing Author)
Medication Therapy Management: A Pharmacotherapy and Medication System
Primer McGraw-Hill 2014

Buffington D
New Codes for Transitional Care Management and Chronic Care Coordination
Services
2012

Isetts B, Buffington D
Coding Principles for Medication Therapy Management Services: The ABCs of CPTs
The Pharmacist's Guide to Compensation for MTM Services, Chapter 6, 2009

Buffington D
Future of medication therapy management services in delivering patient-centered
care
American Journal of Health-System Pharmacy, Sep 2007

Brill J, Buffington D, Downs C, Siegel
Perspectives one year after implementation of the Medicare Prescription Drug
Improvement and Modernization Act: A Socratic Panel Discussion
American Journal of Health-System Pharmacy, Sep 2007

Isetts, B, Buffington D
CPT cod-change proposal: National data on pharmacists' medication therapy
management services
Journal of the American Pharmacists Association, Jul/Aug 2007, 491-495

Buffington D
Pharmacist current Procedural Terminology codes and medication therapy
management
Medicare Modernization Act Q&A
American Journal of Health-System Pharmacists, Vol 63 Jun 2006

Buffington D

Coding Communication: Medication Therapy Management Services

American Medical Association, CPT Assistant, Apr 2006 / Volume 16, Issue 4

Rauck RL, Wallace M, Leong M, Minehart M, Webster L, Charapata S, Abraham J,
Buffington D, Ellis D, Kartzinel R, et al

A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in
Adults with Severe Chronic Pain

Journal of Pain and Symptom Management, 2006; 31:393-406

Turner JL, Kosstman JR, Aquino A, Wright D, Szabo S, Bidwel RI, Goodgame J, Daigle A,
Kelley E, Jensen F, Duggy C, Carlo D, and Moss RB

The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-
specific immunity in a double-blind, randomized, adjuvant-controlled subset study in
HIV infected subjects regardless of concomitant antiviral drugs

HIV Medicine, Buffington D, Editorial Panel, Research Site, 2001 2, 68-77

Buffington D

Improving Our Communications Via the Internet

Florida Journal of Health-System Pharmacy, Volume 18, Number 3, Jan 2001

Buffington D, et al

Sparfloxacin for the treatment of acute bacterial maxillary sinusitis documented by
sinus puncture

Annual Allergy Asthma Immunology, 2000; 84:63-71 Volume 84, Jan 2000

Poirier S, Buffington D, Memoli G

Billing Third Party Payers for Pharmaceutical Care Services

Annals of Allergy, Asthma and Immunology, Feb 1999

Buffington D, Garrison N, Spector S, Stafford C, Granito K, Zhang H, Talbot G

Sparfloxacin for the Treatment of Acute Bacterial Maxillary Sinusitis

Manuscript for Rhone-Poulenc Rorer, Nov 1997

Buffington D

Identifying Profitable Areas of Expansion: Obtaining Reimbursement

American Society of Health-System Pharmacists, Center on Pharmacy Practice
Management, Oct 1997

Buffington D

Reimbursement for Pharmacy Services

Specialists Spectrum, ASHP, Vol.1, No.1, p.3, Fall 1994

Buffington D, Lampasona V, Chandler M.

Computers in Pharmacokinetics: Choosing Software for Clinical Decision Making

Clinical Pharmacokinetic, 25 (3):205-216, Oct 1993

Buffington D

Predict what major changes will result from health care reform. What impact will these
changes have on you and how you conduct your business

Florida Journal of Hospital Pharmacists, Vol. 13, No. 4, p. 23, Aug 1993

Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC

Vancomycin Pharmacokinetics and Neonates in Infants: A Retrospective Evaluation

Annals of Pharmacotherapy, Apr 1993;27:490-6

Pritchard J, Buffington D

Is varicella immune globulin (VZIG) an appropriate therapy for the treatment of chicken pox

Florida Journal of Hospital Pharmacy, Vol. 13, No. 3, Jul 1993:29-30

Perkins J, Buffington D, Hoffman M

Gynecologic Malignancies (Chapter 120)

Pharmacotherapy (Second Edition)

Buffington D, Wallach P

Is methemoglobinemia associated with dapsone therapy?

Florida Journal of Hospital Pharmacy, Vol. 13, No. 1, Feb 1993:29

Morton T, Buffington D

Post-graduate pharmacy training programs in Florida

Florida Journal of Hospital Pharmacy, Vol. 13, No. 1, Feb 1993:29-31

Buffington D, Toney J

Focus on temafloxacin: A new rapidly absorbed, extended-spectrum fluoroquinolone antibiotic

Hospital Formula, Jan 1992:27:241-247

Buffington D

Injectable Nonsteroidal Anti-inflammatory: Alternative to Narcotics

Hospital News p. 16, Mar 1991

Buffington D

How is alfa interferon being used in the treatment of cancer?

Florida Society of Hospital Pharmacist Digest, Feb 1991

Buffington D

New medication helps protect the bladder during chemotherapy

Hospital News p. 19, Jan 1991

Buffington D

The Fluoroquinolones and Theophylline: A Potential for Interaction

Pharmacotherapy Forum Vol.1/No.1, Oct 1990

Buffington D

Word Processors and desktop publishing put shine on drug utilization reviews

Drug Utilization Reviews Vol.5/No.4, Apr 1989

Buffington D

Ticar7 and Timentin7: Recent Formulary Changes

EUH/Antibiotic Use Reviews, Oct 1987

Buffington D

Methicillin-Resistant Staphylococcus Aureus (MRSA)

DGH/Pharmacy News, May 1986

Gilmore R, Russell J, Buffington D

Legislative Review of Georgia's Third-Party Prescription Programs

Georgia Pharmaceutical Association, May 1986

Toler SM, Lopez AV, Buffington D

Smoking and the fetus - What You Should Know

Georgia Pharmaceutical Association Journal, (Computer Graphics)

RESEARCH PROTOCOLS:

2015

COV02520124: An Open-Label, Safety and Pharmacokinetic Study of Hydromorphone Hydrochloride Extended-Release Tablets (Once-Daily Hydromorphone) in Opioid-Tolerant Pediatric Subjects with Chronic Pain

2012

D3820C0005: A Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

2011

D3820C0004: A Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

GWCA0999: A multicenter, non-comparative, follow-on study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) therapy in patients with cancer related pain.

GWCA0958: A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy

2010

CQAB149B2223: A multi-center, randomized, double-blind, placebo controlled, parallel group, repeated-dose study to evaluate the efficacy, safety, tolerability and pharmacokinetics of three different dosing regimens of inhaled indacaterol maleate in patients with persistent asthma

2009

The SWIFT Study: A Prospective, Randomized, Open-Label Phase IV Study to Evaluate the Rationale of Switching from Fixed-Dose Abacavir (ABC)/ Lamivudine (3TC) to Fixed-Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically-Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Regimen GS-US-164-0216

Blood Pressure and Metabolic Effects of Nebivolol Compared with Hydrochlorothiazide and Placebo in Hypertensive Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose Protocol ID: NEB-MD-04

A double blind, randomized, placebo controlled, parallel group dose-range exploration study of Sativex® in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy
GWCA0701

2005

An Open-Label, 12-Month Study to Evaluate the Safety, Tolerability, and Efficacy of ORAVESCENT® Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Non-cancer Pain C25608/3040/BP/US (Cephalon)

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT® Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Neuropathic Pain C25608/3041/BP/US (Cephalon)

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT® Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Low Back Pain C25608/3042/BP/US (Cephalon)

Survey to Assess the Prevalence, Characteristics, and Impact of Breakthrough Pain in Chronic Pain Patients with and without Cancer Managed by Clinicians Who are not Pain Specialists SMI05002

2004

THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF ACAM2000 SMALLPOX VACCINE IN ADULTS WITH PREVIOUS SMALLPOX VACCINATION. A Randomized, Double-Blind, Fixed Dose, Phase 3 Comparison between ACAM2000 and Dryvax® Smallpox VaccinesH-400-012 (Acambis)

A Multicenter, Phase 3 Study to Confirm the Safety and Efficacy of Intravenous Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis DORI-06 (Peninsula Pharmaceuticals)

THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF ACAM2000 SMALLPOX VACCINE IN ADULTS WITHOUT PREVIOUS SMALLPOX VACCINATION. A Randomized, Double-Blind, Fixed Dose, Phase 3 Comparison between ACAM2000 and Dryvax® Smallpox VaccinesH-400-009 (Acambis)

An Open-Label, Long Term, Multi-Center, Intrathecal Ziconotide (PRIALT™) Effectiveness And Safety Trial (ZEST) In Patients With Chronic Severe Pain ELN92045-501

A Multi-Center, Open-Label, Long-Term Study of OraVescent® Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid-Tolerant Cancer Patients 099-15 (CIMA)

A Multi-Center, Double-Blind, Placebo-Controlled Study of OraVescent® Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid-Tolerant Cancer Patients 099-14 (CIMA)

2003

A multicenter, international, randomized, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous SanOrg 34006 with the combination of (LMW)Heparin and vitamin K antagonist (VKA) in the treatment of acute symptomatic pulmonary embolism P64714 / EFC 3484 (Organon/Sanofi)

An Open-label, Multicenter Study of the Safety and Efficacy of Combined Intrathecal Infumorph and Ziconotide (Prialt): Addition of Infumorph in Patients Receiving Prialt for Severe Chronic Pain ELN92045-201 (Elan Pharmaceuticals)

A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease 091-051 (Sepracor)

2002

A Phase III, Vehicle-Controlled Study of Topical Resiquimod (R-848) 0.01% Gel Applied 2 Times per Week for 1 Week for Each Recurrence of Anogenital Herpes over 52 Weeks Study 1452-RESI (3M Pharmaceuticals)

A Retrospective, Case-Control Study to Investigate Genetic Polymorphisms in HIV Infected Subjects Who Developed Hypersensitivity Following Treatment with Abacavir CNA30032 (GlaxoSmithKline)

Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days per Week for the Treatment of Actinic Keratoses on the Head 1447-IMIQ (3M Pharmaceuticals)

An Open-label, Long-term, Multicenter Study of Ziconotide Administered Intrathecally ELN92045-352 (Elan Pharmaceuticals)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF INTRATHECAL ZICONOTIDE IN ADULTS WITH SEVERE CHRONIC PAIN ELN92045-301 (Elan Pharmaceuticals)

AN OPEN-LABEL, LONG-TERM, MULTICENTER STUDY OF ZICONOTIDE ADMINISTERED INTRATHECALLY ELN92045-351, IND # 45,718 (Elan Pharmaceuticals)

A Case Control Investigation Exploring the Relationship Between Gene Variants (HAPTM Markers) and Agranulocytosis or Granulocytopenia In Adult Patients Treated With Clozapine

A 6-month open label, multi-national, effectiveness, and safety study of Elidel® (pimecrolimus) Cream, 1% in subjects with atopic dermatitis Novartis CASM981 C2405

2001

APV30001: A Phase III, randomised, multicenter, parallel, open-label study to compare the efficacy, safety and tolerability of GW433908 (1395mg bid) and Nelfinavir (1250mg bid) over 48 weeks in antiretroviral therapy naïve HIV-1 Infected Adults (Glaxo Welcome)

APV30005: An open-label phase III study to assess the long-term safety profile of GW43398 containing regimens in HIV-1 infected subjects (Glaxo Welcome)

A Phase II, Randomized, Double-Blind, Vehicle-Controlled, Dose Frequency Response Study of Topical Resiquimod (R-848) Gel Applied to Anogenital Herpes Lesions Once, Twice or Three Times Per Week for One Recurrence to Prevent Future Recurrences 1411-RESI (3M Pharmaceuticals)

Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days per Week for the Treatment of Actinic Keratoses on the Head (3M Pharmaceuticals)

A prospective, randomized, double blind, multicenter trial assessing the safety and efficacy of sequential (intravenous/oral) BAY 12 -8039 (moxifloxacin) 400 mg every 24 hr compared to intravenous piperacillin/tazobactam 3.0/0.375 g every 6 hr followed by oral amoxicillin/clavulanic acid suspension 800 mg every 12 hr for the treatment of patients with complicated skin and skin structure infections (Bayer)

Protocol #: CPS 2000-01A An Open Label, Phase 1 Study of the Safety and Tolerability of Coccloba uvifera in Healthy Volunteers

Omapatrilat Cardiovascular Treatment Assessment versus Enalapril (OCTAVE) Protocol Number: CV137-120

Protocol Number: CPS.USF.001 An Open Labeled, Single Blind, Patient-Controlled Study of the Safety and Efficacy of Clobetasol Propionate Foam, 0.05% in the Treatment of Alopecia Areata

CNA30021: A phase III, 48-week, randomized, double-blind, multicentre study to evaluate the safety and efficacy of abacavir (ABC) 600mg once-daily (QD) vs abacavir 300mg BID in combination with lamivudine (3TC) (300mg QD) and efavirenz (EFV) (600mg QD) in antiretroviral therapy naïve HIV-1 infected subjects (GlaxoSmithKline)

A Phase III, randomized, multicenter, parallel, open-label study to compare the efficacy, safety, and tolerability of GW433908 1395 mg bid and Nelfinavir 1250 mg bid over 48 weeks in antiretroviral therapy naïve HIV-1 Infected Adults (Glaxo)

A Multicenter Dose Randomized Evaluation of Targretin® Capsules + PUVA In Patients With Stage IB – IIA Cutaneous T-Cell Lymphoma IND No. 61,896 (Ligand)

A Multicenter, Randomized, Open-Label Study Comparing the Efficacy And Safety Of Once Daily (OD) ORG 31 540/SR90107A Versus Adjusted-Dose Intravenous (IV) Unfractionated Heparin (UFH) In The Initial Treatment Of Acute Symptomatic Pulmonary Embolism (PE) (Organon)

Protocol Number: 25000/592. An Open, Non-Comparative Multicenter Study to Assess the Efficacy and Safety of Oral Augmentin® SR 2000/125 mg Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults (Smith-Kline Beecham)

VER001-5: Phase II Pilot, Randomized, Open-Label, Multi-center Study to Evaluate the Safety and Efficacy of Dalbavancin (V-Glycopeptide) Versus Investigator/Physician Designated Comparator in Skin and Soft Tissue Infection IND # 60,613 (Vericor)

2000

A Phase III, Multicenter, Randomized, Parallel Group, Evaluator Blinded, Comparative Study to Evaluate the Effectiveness and Safety of "Topical Otic CILODEX™ (ciprofloxacin 0.3%, dexamethasone 0.1%) Suspension Compared to CILOXAN® (ciprofloxacin 0.3%) Solution and CORTISPORIN® Suspension (neomycin 0.35%, polymyxin 10,000 IU/mL, hydrocortisone 1.0%) for Treatment of Patients with Moderate to Severe Acute Otitis External

1999

Protocol Title: Safety and Efficacy of Intravenous HMR4396 and Epogen® for the Management of Anemia in Subjects with Chronic Renal Failure Requiring Hemodialysis HMR4396A/3001

An Open-Label, Long-Term Safety and Tolerability Study of Ziconotide® Administered Intrathecally to Patients with Chronic, Severe Pain (Elan Pharmaceutical s)

1998

A One-Year Randomized, Double Blind, Placebo Controlled Study of Alosetron (GR68755) 1mg BID in Female Subjects with Irritable Bowel Syndrome S3B30006

A Open, Non-Comparative Multicentre Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125 mg, Twice Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults, Protocol BRL-02500/551 (Smith-Kline Beecham)

1997

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 units of HIV-1 Immunogen Compared to IFA Alone Every 12 Weeks on AIDS-Free Survival in Subjects with HIV Infection and CD4 T Lymphocytes Between 300-549 cells mcg Regardless of Concomitant HIV Therapies Protocol IRC-806 (Immune Response Corporation)

A Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Oral Lobucavir In Patients With Recurrent Herpes Labialis, AI459-012 (Bristol-Myers Squibb)

A Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Oral Lobucavir In Patients With Recurrent Genital Herpes, AI459-011 (Bristol-Myers Squibb)

Phase II Multi-Center, Randomized, Placebo-Controlled, Two-Step Dose-Escalation Safety, Tolerability, and Hypothesis Generating Trial of Recombinant Tissue Factor Pathway Inhibitor (rTFPI), SC-59735 in Sepsis Patients, Protocol CS-TF004 (Chiron)

1996

A Randomized, Double-Blind, Multicenter Trial Assessing the Safety and Efficacy of a Single Intravenous Dose of CP-116,517 (alatrofloxin) Compared with Cefotetan for the Prophylaxis of Infection Following Colorectal Surgery #154-128 (Pfizer Central Research)

1995

Pfizer 154-128 Colo-Rectal Prophylaxis (Pfizer)

Pfizer 154-124 Intraabdominal Infections (Pfizer)

Matrix 66-94-2 5 FU/epi Basal Cell Carcinoma (Matrix)

RPR 106972 Streptogramin Sinusitis (Rhône-Poulenc Rorer)

Oral Cefpodoxime Proxetil (Vantin®) Tablets in the Treatment of Acute Maxillary Sinusitis in Adults #M/116/40/0108. (Upjohn Company)

A Double Blind, Comparative Study of the Efficacy and Safety of Orally Administered OPC-17116 and Clarithromycin in the Treatment of Patients with Community Acquired Pneumonia #106-94-206 (Otsuka America Pharmaceuticals, Inc.)

A Prospective, Randomized, Double-Blind, Parallel, Control, Multicenter Trial Comparing The Efficacy and Safety of 1% terbinafine (Lamisil®) Cream Applied Once Daily to Placebo In The Treatment of Cutaneous Candidiasis SFC-352 (Sandoz Pharmaceuticals)

1994

Multicenter, Randomized, Partially Blind, Parallel Group, Clinical Trial to Compare the Efficacy and Safety of Twice and Once Daily Subcutaneously Administered Enoxaparin and Continuous Infusion Heparin in the Treatment of Patients with Deep Vein Thrombosis and Pulmonary Embolism RP-54536-529 (Rhône-Poulenc Rorer)

Multicenter, Double Blind, Comparative Study of Intravenous meropenem (Merrem®) and imipenem (Primaxin®) for the Treatment of Nosocomial Lower Respiratory Tract Infections 359IL/0059 (Zeneca Pharmaceuticals)

Open, Non-comparative, Multicenter Study of RP64206 Sparfloxacin in the Treatment of Acute Bacterial Maxillary Sinusitis RP64206-359 (Rhône-Poulenc Rorer)

A Double-Blind, Parallel Group, Randomized Trial to Compare the Efficacy and Safety of Enoxaparin 40mg SC QD and Unfractionated Heparin 5000 IU SC TID During 6-12 Days for Prevention of Deep Vein Thrombosis (DVT) in 800 Evaluable Patients After Planned Elective Curative Cancer Surgery RP-54563-567 (Rhône-Poulenc Rorer)

A Double-Blind Multinational Trial Comparing Sorivudine (BV-araU) (SQ 32,756) vs. Acyclovir for the Treatment of Acute Localized Herpes Zoster and the Effect on Zoster-associated Pain In Immunocompetent Subjects. BMS-AI458-072-008 (Bristol Myers Squibb)

Assessment and Analysis of Risk Factors for the Development of Candidemia in Hospitalized Patients, (Pfizer)

1993

Pharmacoeconomic Analysis of Systemic Antifungal Prescribing Patterns. (Pfizer/Roerig)

A Multicenter, Double-Blind Comparative Study of Intravenous Merrem (Meropenem) and Primaxin (imipenem-cilastatin) for the Treatment of Intra-Abdominal Infections. (Zeneca)

A Multicenter, Double-Blind Comparative Study of Intravenous Merrem (Meropenem) and Primaxin (Imipenem-Cilastatin) for the Treatment of Nosocomial Lower Respiratory Tract Infections (Zeneca)

Double Blind, Placebo-Controlled Study of the Efficacy and Safety of three doses of CP-127 and Placebo in Patients with Presumed Sepsis and the Systemic Inflammatory Response Syndrome (SIRS) CP-0127-92-002 (Cortech, Inc)

Double Blind, Randomized, Comparative Study of RP-64206 (Sparfloxacin) vs. Cefaclor in the Treatment of Community-Acquired Pneumonia (Rhone-Poulenc Rorer)

A Randomized, Double Blind, Placebo-Controlled, Multicenter Study of Oral GR122311X Compared with Ranitidine and GR88502X for the Prophylaxis of Nonsteroidal Anti-Inflammatory Drug Associated Gastric or Duodenal Ulcers in Patients with Osteo- or Rheumatoid Arthritis and without a History of Gastric or Duodenal Ulcers (Glaxo)

Prospective, Randomized, Third Party-Blind, Study to Compare the Safety and Efficacy of Ciprofloxacin (Sequential IV/PO) with Intravenous Ceftazidime and Tobramycin in the Treatment of Pediatric Cystic Fibrosis Patients with Acute Pulmonary Exacerbation D91-024, BAY o9867m BAY q3939 (Miles, Inc)

A Multicenter, Open-Label Treatment Protocol to Provide Aerosolized rhDNase Therapy to Patients with Cystic Fibrosis. rhDNase Protocol Z0507g-A2 (Genetech)

A Multicenter Epidemiologic Protocol to Evaluate Pulmonary Function and the Rate of Respiratory Tract Infections in Patients with Cystic Fibrosis rhDNase Z0525n (Genetech)

Lorabid, 200 mg vs. 400 mg BID in Sinusitis with Bacteriology. Lorabid Protocol B9U-MC-AZBX(b) IND No. 29957, NDA No. 50-668 (Eli Lilly)

Uncomparative Study of Sparfloxacin in Acute Sinusitis (Rhone-Poulenc Rorer)

1992

Comparison of the Safety and Efficacy of Cefodizime versus Ceftriaxone in the Treatment of Complicated Urinary Tract Infections. Cefodizime CSZ-300 (Fujisawa Pharmaceutical Corporation)

A Multicenter, Double-blind, Randomized, Comparative Study of the Efficacy and Safety of Temafloxacin Intravenous/Oral Sequential Therapy Versus Cefuroxime with or without Erythromycin Intravenous/Oral Sequential Therapy in the Treatment of Hospitalized Patients with Community Acquired Pneumonia. Temafloxacin #M91-651. (Abbott Laboratories)

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety and Efficacy of Aerosolized Recombinant Human DNASE I (rhDNase) in Patients with Cystic Fibrosis (Genentech, Inc.)

Centocor: HA-1A™ Efficacy in Septic Shock Trial CHESS #C0041T20 (Centocor, Inc.)

A Randomized, Double-Blind Repeat-Dose Crossover Study to Determine the Safety and Efficacy of sustained Versus Immediate Release Codeine Sulfate on Chronic Cancer Pain. Codeine #CSR-0192 (Roxane Laboratories)

A Randomized, Double-Blind Comparative Study of the Safety and Efficacy of Sustained Versus Immediate Release Codeine Sulfate in the Treatment of Chronic Cancer Pain. Codeine #CSR-0292 (Roxane Laboratories.)

A Multicenter Randomized, Double Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GR122311X Compared with GR88502X, Ranitidine and Placebo in Patients with Duodenal Ulcer. Ranitidine #H2B-302 (Glaxo, Inc.)

A Multicenter Randomized, Double-Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GR122311X Compared with GR88502X, Ranitidine and Placebo in Patients with Benign Gastric Ulcer. Ranitidine #H2B-312 (Glaxo, Inc.)

A Multicenter, Open-Label Treatment Protocol to Provide Aerosolized rhDNase Therapy to Patients with Cystic Fibrosis (Genentech, Inc.)

Prospective, Double Blind, Controlled, Randomized, Multi-Center Comparison of the Safety and Efficacy of Intravenous Ciprofloxacin Versus Intravenous Imipenem for the Treatment of Patients with the Sepsis Syndrome (Miles, Inc.)

RENOVA for the Treatment of Photo damaged Skin (Ortho Pharmaceuticals)

A Multicenter, Controlled Evaluation of the Safety and Efficacy of Repeated Oral Doses of Vicoprofen (hydrocodone bitartrate with ibuprofen) for the Treatment of Chronic Pain. Vicoprofen VP-04 IND No. 29498 (Knoll Pharmaceuticals)

1991

A Prospective Comparison of Ondansetron (IV) and Dexamethasone (PO) Versus Prochlorperazine (PO) and Dexamethasone (PO) for the Prevention of Post Chemotherapy Related Nausea and Vomiting

A Comparative Study of the Safety and Efficacy of BIOLID versus EES in the Treatment of Group A Beta-Hemolytic Streptococcal Pharyngitis. BIOLID BE-C200 (Belmac Corporation)

1989

A Randomized, Prospective, Comparative Study of the Efficacy of Cefoperazone/Sulbactam Versus Ceftazidime Plus Vancomycin Versus Ticarcillin Plus Gentamicin in Febrile Neutropenic Patients. Cefoperazone/Sulbactam 88-S-137. (Pfizer)

1988

An Open, Prospective Study to Evaluate the Incidence of Prothrombin Time Elevation and Clinical Bleeding in Patients Receiving One of Ten Selected Antibiotics. PT Elevation 88-R-041. (Pfizer Pharmaceuticals)

Imipenem-Cilastatin Efficacy, Tolerability and Economic Comparisons to Combination Antibiotic Therapy. Imipenem-Cilastatin.

A Comparison of Ampicillin/Sulbactam Versus Cefoxitin in the Prevention of Infections Complicating Radical Abdominal Hysterectomy. Ampicillin/Sulbactam 87-S-421. (Pfizer Pharmaceuticals)

Evaluation of Antibiotic Prophylaxis in Open Heart Surgery.

A Study of the Cost of Administration of Vancomycin and a Comparison with Alternative Antibiotic Therapy. Vancomycin. (Merrell Dow Pharmaceutical, Inc.)

1987

Evaluation of Gentamicin Levels Obtained from Hickman Catheters in a Hematology Population. Hickman Catheters HIC-118-87

PRESENTATIONS:

- 09-15-23 **White Coat Ceremony - Keynote Speaker**
University of South Florida Taneja College of Pharmacy
Tampa, FL
- 07-05-23 **The Future of Pharmacy: Challenges and Opportunities**
Florida Pharmacy Association Annual Meeting
Marco Island, FL
- 05-11-22 **Medication Therapy Management and Collaborative Practice**
Nova Southeastern
Tampa, FL
- 03-05-22 **Provider Status Update**
Florida A&M University 45th Annual Leonard LeBaron Inge
Clinical Pharmacy Symposium
Tampa, FL
- 10-20-21 **Keynote: Innovation in Pharmacy Practice**
2021 Annual Feurt Symposium
University of Tennessee, College of Pharmacy
Memphis, TN
- 10-15-21 **Point-of-Care Testing Certification Course**
Florida Pharmacy Association
Orlando, FL
- 06-24-21 **Navigating Reporting and Coding Solutions for Pharmacist
Integration in New Care Delivery Systems**
American Academy of Professional Coders (AAPC)
Virtual Conference
- 04-18-21 **Clinical Practice Update: Florida Pharmacy Practice and
Physician Collaboration**
Florida Pharmacy Association Regulatory and Law Conference
Tampa, FL
- 12-5-6-20 **Advanced Pharmacy Practice Models: Practice Update**
Florida Pharmacy Association Regulatory and Law Conference
Sarasota, FL
- 08-08-20 **Billing Mechanisms for Pharmacists' Clinical Services: Emerging
Opportunities**
Florida Society of Health-System Pharmacist
Virtual Conference
- 05-01-20 **Taneja College of Pharmacy Class of 2020 Medallion and
Awards Ceremony**
Virtual Conference

- 04-17-20 **Keynote: Future Vision and Opportunities in Pharmacy Practice**
University of Pittsburgh P2 Keynote Presentation
Video Conference
- 03-27-20 **Interoperability and Health Information Exchange**
TCOP Medical Informatics and Technology (MIT) Course
University of South Florida
Tampa, FL
- 11-07-19 **Overview of Medication Therapy Management: Yesterday,
Today and Tomorrow's Opportunities**
2019 American Society of Consultant Pharmacists Annual
Meeting and Exhibition
Grapevine, TX
- 10-23-19 **Pharmacology & Toxicology: Family Court Updates**
Hillsborough County Bar Association – Marital & Family Law
Chester Ferguson Law Center
Tampa, FL
- 10-13-19 **Frontotemporal Degeneration: Treatment Update**
FTD Patient Support Group Meeting
Tampa, FL
- 08-30-19 **Keynote: White Coat Ceremony**
Marshall University
Charleston, WV
- 08-12-19 **Importance and Benefits of Joining and Being Active in
Professional Associations**
University of South Florida – ITEHC PDU
Tampa, FL
- 07-20-19 **PBMs – The Functional Role and the Dilemmas**
Louisiana Pharmacists Association Annual Convention and
Trade Show at L'Auberge Casino Resort
Lake Charles, LA
- 06-09-19 **Successful Clinical Pharmacy Service and Medication Therapy
Management Practice Models**
University of South Florida, College of Pharmacy Continuing
Education Conference
Tampa, FL
- 06-08-19 **Innovation and Leadership: Evolving Pharmacy Practice**
Kappa Psi Leadership Conference
University of South Florida, College of Pharmacy
Tampa, FL
- 06-07-19 **Law: Advanced Pharmacy Practice Models: Transitions of Care
Management**
Sixth Annual Schwarting Senior Symposium
Springfield, MA
- 05-01-19 **Keynote Speaker: Commencement Address**
University of South Florida, College of Pharmacy
2019 Graduation Ceremony
Tampa, FL

- 03-05-19 **Pharmacist-Guided Exemplary Opioid Management Practices**
Center for Medicare and Medicaid Services
Teleconference – CMS & AMA
Tampa, FL
- 11-28-18 **Health Information and Quality Outcome Initiatives in CMS
Development and Use of Clinical Documentation and Billing
Codes for Pharmacists' Patient Care Services**
Pharmacy Health Information Technology Collaborative (PHIT)
Washington, DC
- 09-12-18 **Prescription Drug Monitoring Programs**
The Opioid Safety Project American Medical Association
PDMP
Opioid Webinar Lecture Series
- 08-04-18 **Strategies for Development and Expansion of Pharmacy
Extenders: Thinking Outside the Box**
Florida Society of Health-System Pharmacists Association 52nd
Annual Meeting – Leadership Track
Orlando, FL
- 05-09-18 **Advanced Practice Models: Transitions of Care**
American Society of Consultant Pharmacist
Tampa, FL
- 07-28-17 **DUI: Extrapolation, Medical v. Legal Draws, etc.**
Florida Public Defender Association, Summer Training Program
Bonita Springs, FL
- 07-13-17 **Innovations in Pharmacy Practice**
Florida Pharmacy Association
127th Annual Meeting and Convention
Orlando, FL
- 07-01-17 **Medication Therapy Management in 340B Clinics**
Health Choice Network's 23rd Annual Educational Conference
Boca Raton, FL
- 04-24-17 **Advanced Clinical Pharmacy Practice Update**
Pharmacy Deans' Forum
National Association of Chain Drug Stores Annual Meeting
Scottsdale, AZ
- 04-19-17 **Emerging Payment Models for Physicians: What Does it Mean
for AMCP Members and Medication Management?**
Academy of Managed Care Pharmacy
Webinar Presentation
- 03-25-17 **Creating a Successful Specialty Pharmacy**
American Pharmacists Association Annual Meeting
San Francisco, CA
- 03-16-17 **Medication Therapy Management (MTM), Clinical Research,
and Forensic Pharmacy**
University of South Florida Pharmacy Skills Lecture
(Clinical & Forensics)
Tampa, FL

- 03-14-17 **Pharmacy Practice Opportunities and Legislative Update**
2017 Florida Pharmacists Legislative Days and Health Fair
Pharmacy Advocacy Efforts
Tallahassee, FL
- 02-18-17 **Kappa Psi Ideals: How They Can Shape Your Future and Ensure Your Success**
Keynote Speaker
Kappa Psi Spring Assembly
Tampa, FL
- 02-01-17 **Pharmacists' Reimbursement: Coding & Practice Model Update**
Pharmacy HIT Collaborative Council Face to Face Meeting
American Pharmacist's Association
Washington, DC
- 01-26-17 **Current Issues/Advocacy – Pharmacy Reimbursement**
Shenandoah University
Winchester, VA
- 10-25-16 **Keynote Speaker**
FSHP Mentor Dinner
University of South Florida
Tampa, FL
- 10-13-16 **Provider Status Update**
Hillsborough County Pharmacist Association
Tampa, FL
- 10-03-16 **Making Your Goals a Reality**
Mentoring Hour and Leadership Presentation
University of South Florida
Tampa, FL
- 08-12-16 **Keynote Speaker**
Larkin Health Sciences Institute, College of Pharmacy
White Coat Ceremony
Miami, FL
- 06-30-16 **Pharmacy Practice Update: CMS Update and Reimbursement**
Florida Pharmacy Association
Ft. Lauderdale, FL
- 06-24-16 **Establishing and Paying for New Models of Pharmacy Care**
Medical College of Wisconsin, College of Pharmacy
Milwaukee, WI
- 02-01-16 **USF AMCP Student Group Lecture**
Tampa, FL
- 02-20-16 **Pharmacist's Reimbursement: Current and Future Trends**
American Association of Colleges of Pharmacy
Tampa, FL

- 02-11-16 **National Progress Toward a Health System that Supports Pharmacist Clinical Services**
The 3rd USC Conference on Optimizing Medication Safety and Healthcare Quality: Best Practices and Collaborations for Public Health, Geriatrics, and Mental Health
University of Southern California
Los Angeles, CA
- 08-12-15 **U.S. Healthcare Reform and Its Impact on Pharmacy Practice**
University of South Florida, College of Pharmacy
Tampa, FL
- 08-09-15 **Ask the Experts Panel: Provider Status**
Florida Society of Health-System Pharmacists Association
Orlando, FL
- 08-09-15 **MTM Services with a Focus on Provider**
Florida Society of Health-System Pharmacists Association
Orlando, FL
- 06-26-15 **Profession & Career Planning: Expanding Your Horizons**
Florida Pharmacy Association 2015 Annual Meeting
St. Augustine, FL
- 04-18-15 **Medicare & Health Care Reform: Opportunities for Pharmacists**
Florida Pharmacy Association Law and Regulatory Conference
Tampa, FL
- 03-16-15 **Recognizing Pharmacists as Providers: Expanding Scope of Practice**
South Carolina Society of Health-System Pharmacists Annual Meeting
Hilton Head Island, SC
- 02-21-15 **Pharmacists Influencing Positive Health Outcomes**
Virginia Pharmacist's Association Midyear Meeting
34th Annual Rooke Award Lecture
Roanoke, VA
- 01-10-15 **Defining Your Path as Leaders... Oh the Places You'll Go!**
Florida Pharmacy Association Leadership Conference
Orlando, FL
- 12-06-14 **What Is Pharmacist Provider Status and Why Is It Necessary**
Florida Pharmacy Association Law and Regulatory Conference
Sarasota, FL
- 11-06-14 **Protecting Your Patient and Yourself: Universal Precautions, the Pharmacist, and Ebola**
American Society of Consultant Pharmacists (SCP) 2015 Annual Meeting
Orlando, FL
- 08-25-14 **Future of Pharmacy Curricula: Blending Clinical & Entrepreneurial Skills**
University of Virginia College of Pharmacy, Visiting Faculty
Virginia Commonwealth University School of Pharmacy
Richmond, VA

- 07-10-14 **Innovative Health Care Solutions: The Impact of Integrating Pharmacist's Services**
124th Annual Florida Pharmacy Association Meeting
Ft. Lauderdale, FL
- 12-07-13 **Update on the Provider Status and MTM Reimbursement**
Florida Pharmacy Association
Regulatory and Law Conference
Sarasota, FL
- 09-08-13 **Update on the Provider Status and MTM Reimbursement**
Florida Pharmacy Association
Regulatory and Law Conference
Ft. Lauderdale, FL
- 07-13-13 **Florida Healthcare Law Update**
University of Florida, College of Pharmacy
FPA Gator Reception
Orlando, FL
- 07-13-13 **MTM Practice Models and CPT Coding Update**
123rd Annual Meeting and Convention
Florida Pharmacy Association
Orlando, FL
- 05-03-13 **Medicare Provider Status for Pharmacists**
University of Florida, College of Pharmacy
Spring National Advisory Board Meeting
Orlando, FL
- 04-04-13 **Employer-based Initiatives: Role of the Pharmacists in Transition of Care.**
Transition of Care & Readmissions Boot Camp
36th Annual Conference, Survive and Thrive in the Changing Health Care Environment
American Board of Quality Assurance & Utilization Review Physicians (ABQAURP)
Tampa, FL
- 03-22-13 **The Future of Pharmacy: Your Vision, Your Plan?**
National Student Pharmacist Compounding Competition,
University of Florida College of Pharmacy
Gainesville, FL
- 03-23-13 **MTM Coding: Current Procedural Terminology**
National Student Pharmacist Compounding Competition,
University of Florida College of Pharmacy
Gainesville, FL
- 11-03-12 **Strategic Positioning of MTM Services and Reimbursement in HealthCare Reform**
Nova Southeastern University
Ft. Lauderdale, FL
- 07-20-12 **Medication Therapy Management: Emerging Payment Options**
Georgia Society of Health-System Pharmacists
2012 Summer Meeting
Amelia Island, FL

- 06-24-12 **Compensation for MTM Services: Where We've Been And Where We're Going**
American Pharmacist's Association
MTM Emerging Opportunities (McKesson Meeting)
Las Vegas NV
- 03-31-12 **Opiate Metabolism: Dangerous Interactions**
Prescribing in an Epidemic – Uniting Medical, Legal & Corporate Entities in Fighting America's Deadly Epidemic
Gulf Stream, FL
- 03-10-12 **Compensation for MTM Services: Where We've Been and Where We're Going**
American Pharmacist's Association Annual Meeting 2012
New Orleans, LA
- 02-16-12 **Overview CDTM with metrics Measurement-Inpatient and Ambulatory Practice**
CDTM Summit
New York State Council of Health-system Pharmacists
Albany, NY
- 10-17-11 **ACCP Meeting**
Challenges to Expanding the Scope of Clinical Pharmacy
Pittsburgh, PA
- 10-17-11 **Challenges to Expanding the Scope of Clinical Pharmacy**
American College of Clinical Pharmacy Annual Meeting
Pittsburgh, PA
- 08-27-11 **Prescribing in an Epidemic**
Associates in Emergency Medical Education
Tampa, FL
- 05-26-11 **Collaborative Drug Therapy Management as a Tool for Medication Therapy Management**
34th Annual Schwarting Symposium Presentation
Hartford, CT
- 12-04-10 **Developing ED practice models to ASHP Emergency Medicine PRN**
45th Annual Midyear Meeting
Anaheim, CA
- 09-18-10 **Healthcare Reform Update**
Central Florida Society of Health-System Pharmacists
Orlando, FL
- 07-17-10 **Summer Seminar**
University of Florida
Tampa, FL
- 04-28-10 **Therapy Management: Rheumatology and High Cost Agent**
Lake Erie College of Osteopathic Medicine (LECOM)
Bradenton, FL

- 02-26-10 **The Current Healthcare Environment: Where Does Medication Therapy Management Fit it?**
Florida A & M University
33rd Annual Clinical Pharmacy Symposium
Tallahassee, FL
- 12-09-09 **Educating Patients about Gene Therapy: Information and Tools**
44th Annual Midyear meeting
American Society of Health-System Pharmacists
Las Vegas, NV
- 12-08-09 **Submitting Medical Service Claims for Pharmacists' Clinical Activities**
44th Annual Midyear meeting
American Society of Health-System Pharmacists
Las Vegas, NV
- 11-06-09 **Medication Therapy Management and CPC codes for Reimbursement**
University of Florida COP 2009 Dean's National Advisory Board Meeting
Gainesville, FL
- 09-25-09 **Journal Club Session**
University of Florida Fall Faculty Workshop Conference
Orlando, FL
- 09-19-09 **Pharmacy Managed Hyperlipidemia Clinic: Practice Models and Payment Mechanisms for Clinical Services**
Southwest Florida Society of Health-System Pharmacy
Tampa, FL
- 07-31-09 **Reaching Milestones MTM**
Florida Society of Health-System Pharmacists
43rd Annual Meeting
Orlando, FL
- 07-11-09 **Pharmacy Managed Hyperlipidemia Clinic: Practice Models and Payment Mechanisms for Clinical Services**
Florida Pharmacy Association 119th Annual Meeting and Convention
St. Augustine, FL
- 02-24-09 **Medication Therapy Management, Documentation and Marketing**
Lake Erie College of Osteopathic Medicine (LECOM)
Bradenton, FL
- 01-15-09 **The Profession's Perspective on MTM Documentation and Billing in Providing Effective and Efficient Patient Care**
2009 Annual Industry & Technology Issues Conference
American Society for Automation in Software (ASAP)
St. Petersburg, FL
- 12-09-08 **AMA-CPT Code Development and Update**
2008 ASHP Management Pearls
Orlando, FL

- 12-05-08 **Medication Therapy Management: Getting Paid for Clinical Services**
University of Florida Seminar Presentation
Gainesville, FL
- 11-14-08 **Medication Therapy Management: Getting Paid for Clinical Services**
Keynote Speaker, 2008 Michigan Society of Health-System Pharmacists Annual Meeting
Lansing, MI
- 10-07-08 **Documentation & Billing Standardization**
2008 APHA Foundation Conference
Bethesda, MD
- 09-12-08 **Design and Management of Medical Journal Club**
2008 University of Florida, College of Pharmacy, Dean's Counsel Symposia
Orlando, FL
- 08-25-08 **Medication Therapy Management: What's Next for Community Pharmacy?**
2008 National Association of Chain Drug Stores Pharmacy & Technology Conference
San Diego, CA
- 07-10-08 **The MTMS Business Plan and Dealing with Legal Billing Issues**
Florida Pharmacy Association
Orlando, FL
- 06-08-08 **ASHP Summer Meeting**
Seattle, WA
- 04-12-08 **Strategies for Optimal Therapy in High Risk Patients: Treatment of COPD, Acute Coronary Syndrome & Venous Thromboembolism**
Florida Chapter of American Society of Consultant Pharmacists Senior Care 2008
Tampa, FL
- 04-07-08 **Determining the value of Pharmacy Services and Interventions in the ambulatory care setting**
American College of Clinical Pharmacy
2008 Spring Practice and Research Forum
Phoenix, AZ
- 03-16-08 **Documenting MTM and Patient Care Activities**
APhA 2008 Annual Meeting
San Diego, CA
- 02-09-08 **A Vision for the Future: Developing Pharmacy Practice Models**
Pennsylvania Pharmacists Association 2008 Mid Year Meeting
Harrisburg, PA
- 10-14-07 **Development of Pharmacist Professional Services: The Future of MTMS**
NCPA 109th Annual Convention
Anaheim, CA

- 09-20-07 **Software, Documentation and Billing**
National Association of Chain Drug Stores Meeting, Medication
Therapy Management Services in Community Pharmacy:
Building Process, Partnerships, and Outcomes
Philadelphia, PA
- 06-26-07 **Current Legislative and Regulatory Issues in Pharmacy 2007**
American Society of Health-system Pharmacists –
Summer Meeting
San Francisco, CA
- 05-22-07 **General Session: Perspectives in Practice: Medication Therapy
Management Services**
American Society of Consultant Pharmacists 29th Midyear
Conference
Hollywood, FL
- 05-22-07 **Business Skills 101: Contracting to Provide MTM Services**
American Society of Consultant Pharmacists 29th Midyear
Conference
Hollywood, FL
- 12-04-06 **Impact of the Medicare Modernization Act on Pharmacy
Reimbursement: Lessons Learned at the One Year Benchmark**
American Society of Health-system Pharmacists –
Midyear Meeting
Anaheim, CA
- 11-20-06 **PQA National Meeting**
American Society of Health-system Pharmacists
Washington, DC
- 11-18-06 **Purchasing Medications Through the Internet**
CDMI – Pfizer
Chicago, IL
- 11-16-06 **Understanding CPT Codes**
American Society of Consultant Pharmacists
37th Annual Meeting and Exhibition - Senior Care Pharmacy
Phoenix, AZ
- 11-16-06 **Defining Your Professional Services**
American Society of Consultant Pharmacists
37th Annual Meeting and Exhibition - Senior Care Pharmacy
Phoenix, AZ
- 10-28-06 **Pharmacy Perspective on Quality Issues**
29th Annual Health Care Quality and Patient Safety
Conference Quality: The Pathway to Success
American Board of Quality Assurance & Utilization Review
Physicians
Chicago, IL
- 10-27-06 **Models of Delivery for Patient Care – Future of MTMS**
American College of Clinical Pharmacy
29th Annual Health Care Quality & Patient Safety Conference
Quality: The Pathway to Success
St. Louis, MO

- 10-19-06 **Effective Oncology Benefit Management**
Center for Business Intelligence's Effective Oncology Benefit
Management Conference
Chicago, IL
- 09-29-06 **Pharmacist Service Payment: Blueprint for Success**
Alabama Pharmacy Consensus Conference
Auburn University Harrison School of Pharmacy
Auburn, AL
- 09-20-06 **Opportunities to Implement Compliant MTMP**
HCPro
Online Audio Conference
- 07-09-06 **CPT Coding**
Georgia Society of Health-System Pharmacists
2006 Summer Meeting
Amelia Island, FL
- 05-15-06 **MTM – Focus Presentation**
FMQAI Presentation
Tampa, FL
- 05-05-06 **Emerging Trends in Clinical Medical Management: Value of
Pharmacists Services**
American Board of Quality Assurance & Utilization Review
Physicians (ABQAURP), Medical Management System
Innovations: The Next Generation
Orlando, FL
- 04-28-06 **Pharmacist/Physician Collaboration Strategies**
Walgreen's National Advisory Board Meeting
Rosemont, IL
- 04-27-06 **Medicare Part D and the Expanding Need for Pharmacists
Services**
Pharmacy Society of Wisconsin
Madison, WI
- 04-24-06 **Value of Psychiatric Medicine Debate – Industry and Managed
Care Perspectives**
College of Psychiatric and Neurologic Pharmacists (CNCP)
Annual Meeting 2006
Baltimore, MD
- 04-22-06 **Medicare Part D: The Pharmacist's Role in Patient Management**
National Advisory Board
University of Florida College of Pharmacy
Gainesville FL
- 04-07-06 **Pharmacists Billing Codes: Application in Practice Models**
AMCP 18th Annual Meeting and Showcase
Seattle, WA
- 04-05-06 **Medicare Part D: Prescription Drug Plans and MTMS Benefit
Design**
Academy of Managed Care Pharmacy (AMCP)
18th Annual Meeting & Showcase
Seattle, WA

- 03-23-06 **Medicare/CPT/Hospital**
Catholic Health Partners
Cincinnati, OH
- 02-26-06 **Medicare Reimbursement of Drug Therapy Management**
Tennessee Society of Health –System Pharmacists (TSHP)
Midyear Seminar
Nashville, TN
- 02-20-06 **University of South Carolina**
University of South Carolina College of Pharmacy (USC COP)
Rho Chi Society Banquet,
Columbia, SC
- 02-17-06 **Medication Therapy Management Services: Opportunities for
Pharmacists and Implications for Treatment Options**
American Society of Consultant Pharmacists
2006 Spring Meeting, Hilton Clearwater Beach Resort
Clearwater, FL
- 01-28-06 **Update on Medicare Part D and CPT Codes for Pharmacists'
Services**
Iowa Pharmacy Association
Educational Expo 2006
Des Moines, IA
- 01-25-06 **Update on Medicare Part D and CPT Codes for Pharmacists'
Services**
Pinellas County Pharmacy Association Meeting
Hospice of the Florida Suncoast
Clearwater, FL
- 12-06-05 **Practice Applications in Medication Therapy Management
Services (MTMS) in Medicare Part-D**
American Society of Health-System Pharmacists
Midyear Meeting (ASHP)
Las Vegas, NV
- 12-05-05 **Cutting-Edge Ambulatory Practice Program**
American Society of Health-System Pharmacists
Midyear Meeting (ASHP)
Las Vegas, NV
- 12-03-05 **Impact of Medicare Part D and MTMS on Anticoagulation
Services**
20th Anniversary of the Pharmacy Invitational Conference on
Antithrombotic Therapy (PICAT), Tuscany Suites and Casino
Las Vegas, NV
- 12-03-05 **Selective Issues in Hospital Pharmacy Practice for 2006:
Medicare Part D – It's Here!**
University Health-System Consortium, Pharmacy Council
Las Vegas, NV
- 12-03-05 **Anticoag**
ASHP Midyear Meeting
Las Vegas, NV

- 11-15-05 **Electronic Billing of Non-Dispensing Pharmacy Services**
National Association of Chain Drug Stores (NACDS) 2005
Pharmacy & Technology Conference
San Diego, CA
- 11-12-05 **Clinical Pharmacy Interventions Post MMA**
American Society of Consultant Pharmacists, Senior Care
Pharmacy '05 (ASCP)
36th Annual Meeting Exhibition Course Tracking/Publishing #20-
39948/10-231316
Boston, MA
- 10-26-05 **MMA and Medicare Part D**
AmeriDrug & JSA Medical Group
Tampa, FL
- 09-29-05 **MTMS Presentation**
Florida Hospital Presentation & Consulting
Orlando, FL
- 09-26-05 **MMA and Medicare Part D**
NCPDP Educational Summit
Countdown to MMA: New & Unfinished Business
San Diego, CA
- 09-15-05 **Pharmacist-Based CPT Codes for Medication Management**
The Profession has been recognized with CPT Codes, What
Next?
ASHP Teleconference Seminar
- 08-31-05 **Electronic Billing of Non-Dispensing Pharmacy Services**
National Association of Chains Drug Stores Foundation
(NACDS) 2005 Pharmacy & Technology Conference
San Diego, CA
- 08-16-05 **Current Opportunities in Billing for Pharmacist Clinical Services**
National Council of Prescriptions and Drug Programs (NCPDP)
Educational Summit, Countdown to MMA: New and Unfinished
Business
Philadelphia, PA
- 08-06-05 **Using a PDA to Demonstrate the Value of Clinical Pharmacy
Services**
Florida Society of Health-System Pharmacists (FSHP)
39th Annual Meeting, Gaylord Palms Resort and Convention
Center
Orlando, FL
- 08-02-05 **MTMS Medicare Part D**
Keystone Medical
Philadelphia, PA
- 07-08-05 **Medicare Modernization Act: What we need to Know on
January 1, 2006**
Florida Pharmacy Association (FPA)
115th Annual Meeting and Convention
Marco Island, FL

- 06-23-05 **Show me the Money: Billing & Payment for MTM**
National Association of Chain Drug Stores Foundation
Washington, DC
- 06-16-05 **Develop a Clinical Practice**
Arizona Pharmacy Association (AZPA)
1st Annual Meeting
Phoenix, AZ
- 06-16-05 **Update on Medication Therapy Management Services (MTMS)
and Medicate Part D**
Tampa Bay Residency Forum, St. Bart's Island House
Tampa, FL
- 05-01-05 **How to Start a Clinical Practice**
Arizona Pharmacy Association
1st Annual Convention, Wild Horse Pass Resort ND Spa
Chandler, AZ
- 04-30-05 **Tip Jars for Pharmacists: Current Update on Pharmacist
Reimbursement Trends**
Nova Southeastern University (NSU)
16th Annual Program Contemporary Pharmacy Issues
Davie, FL
- 04-11-05 **Current Opportunities in Billing and the Medicare Drug Benefit**
American College of Clinical Pharmacy (ACCP)
2005 Spring Practice Research Forum/Updates in Therapeutics
Myrtle Beach, FL
- 04-02-05 **Development of Current Procedural Terminology (CPT) Codes
for Pharmacists Services: Implications for Residency Training
Programs**
American Pharmacists Association Community Pharmacy
Residency Program (CPRP)
Annual Meeting 2005
Orlando, FL
- 02-15-05 **Value of Medicine**
Diagnostic Clinic of Largo
Largo, FL
- 12-05-04 **Section Connection**
American Society of Health-System Pharmacists (ASHP)
39th Midyear Meeting
Orlando, FL
- 11-22-04 **Developing an Advanced Pharmacy Practice Model – Position
in the Pharmacist to Meet the Needs of the Healthcare
Marketplace**
National State Executives Association Meeting (NCSPAEE)
Fall Symposium
Marco Island, FL
- 10-21-04 **Treatment of Pulmonary Embolus**
Journal Club for St. Joe's ER, Donatello's
Tampa, FL

- 10-17-04 **To Switch or Not to Switch**
Brevard County Pharmacist's Association
Melbourne, FL
- 09-26-04 **Reimbursement Update**
Nebraska Health-System Pharmacists Association
2004 Annual Fall Seminar
Mahoney State Park, NE
- 09-09-04 **Value of Medicine**
Tampa Bay Association of Health Underwriters, Feather Sound
Country Club
Clearwater, FL
- 08-28-04 **MMA and Reimbursement**
National Association of Chain Drug Stores (NACDS)
2004 Pharmacy & Technology Conference
San Diego, CA
- 08-26-04 **Pancreatic Enzymes in Malabsorption Disorders**
Wake AHEC Meeting
Raleigh, NC
- 07-30-04 **Value of Medicine**
Georgia Society of Health-System Pharmacists
2004 GSHP Summer Meeting
Amelia Island, FL
- 07-08-04 **Medicare Part D and CPT Coding Update**
Florida Pharmacy Association, Pfizer
Marco Island, FL
- 04-30-04 **Medicare Part D and CPT Coding Update**
Nova Southeastern University (NOVA)
Ft. Lauderdale, FL
- 11-15-03 **Documenting and Being Reimbursed for Care and Panel
Discussion Opportunities for Pharmacists and Expanding Their
Practices in Caring for Patients with Dementia, Delirium and
Depression**
Florida Pharmacy Association
Academy of Pharmacy Practice (APP)
Mid-Year Clinical Conference
Orlando FL
- 10-11-03 **Overview of Direct Thrombin Inhibitors**
SouthWest Florida Society of Health-System Pharmacists
2003 Annual Meeting
Professional and Therapeutic Update
Tampa, FL
- 10-11-03 **Antibiotic Treatments in the Inpatient Setting**
SouthWest Florida Society of Health-System Pharmacists
2003 Annual Meeting
Professional and Therapeutic Update
Tampa, FL

- 09-10-03 **Public Debate Forum – Pharmaceutical Importation**
Suncoast Tiger Bay Club
St. Petersburg, FL
- 06-27-03 **New Developments in the Treatment of Erectile Dysfunction
Managed Care Consultancy Panel**
Bayer Healthcare Pharmaceuticals, Sheraton City Centre Hotel,
Salt Lake Centre Hotel
Salt Lake City, UT
- 06-03-03 **Transforming Pharmacy Reimbursement – Planning Your Route:
Applying Reimbursement Strategies to diverse Practice Settings**
American Society of Health-System Pharmacists (ASHP)
Summer Meeting 2003, Learners and Leaders
San Diego, CA
- 06-02-03 **Under Construction: Obtaining Reimbursement for Clinical
Services.**
American Society of Health-System Pharmacists (ASHP)
Summer Meeting 2003, Learners and Leaders
San Diego, CA
- 05-08-03 **Treatment Options for Persistent Asthma**
Merck, Roy's Restaurant
Tampa, FL
- 04-01-03 **Roundtables in Pharmaceutical Care**
American Pharmaceutical Association (APhA)
Annual Meeting & Exposition 2003
Pharmacy Administration and Management
ACPE 202-000-03-087-L04
New Orleans, LA
- 03-31-03 **How to get paid for Pharmaceutical Care**
American Pharmaceutical Association (APhA)
Annual Meeting & Exposition 2003, Pharmacy Administration
and Management ACPE 202-000-03-040-L04
New Orleans, LA
- 03-22-03 **Pharmacy Education and Pharmacy Practice: Improving Health
Outcomes Through the Provision of Comprehensive Pharmacy
Services**
Senate Health Educational and Labor and Pension Committee
Congressional Briefing, United States Capitol, Room S-115
Washington, DC
- 03-13-03 **Peer Discussion Group TOPIC: Treatment Options for Persistent
Asthma**
Merck Speaker, Del Frisco
Winter Park, FL
- 12-10-02 **Ambulatory and Chronic Care Practitioners: Development and
Implementation of collaborative Management plans with other
providers**
American Society of Health-system Pharmacists (ASHP)
37th Annual ASHP Midyear Meeting, The ASHP Section of Home
Atlanta, GA

- 11-13-02 **Clinical Service Reimbursement Workshop**
American Society of Consultant Pharmacists (ASCP)
2002 Senior Care Pharmacy 33rd Annual Meeting and
Exhibition
Anaheim, CA
- 11-10-02 **Reimbursement for Pharmacy Services**
University of Florida, Pharmacy Law and Management
Conference 2002
Orlando, FL
- 10-05-02 **Quinolone Antibiotic Update**
Southwest Florida Society of Health-System Pharmacists
(SWFSHP)
2002 Annual Meeting, Professional and Therapeutic Update
Tampa, FL
- 09-26-02 **The Nuts and Bolts of Billing for Pharmacists' Services, Billing for
Clinical Services**
Iowa Pharmacy Association
Des Moines, IA
- 07-03-02 **Fluoroquinolone Overview Lecture**
Bayer, Primary Care 2002
Kiawah Island, SC
- 06-14-02 **Toxicology and DUI**
DUI Seminar, Hillsborough County Public Defender's Office
Meeting
Tampa, FL
- 06-09-02 **Anti-Infective Treatment of Sinusitis**
Allergy, Asthma, and Immunology Associates
Key Largo, FL
- 06-07-02 **HIV Pharmacology Update**
Florida Allergy, Asthma & Immunology Society
2002 Annual Meeting
Key Largo, FL
- 02-20-02 **Insulin Delivery Devices**
Duval County Pharmacological Society, Novo Nordisk
Jacksonville, FL
- 12-13-01 **Avelox Clinical Advisory Panel**
Bayer - Stratagem Plus, Inc., Donatello's
Tampa, FL
- 12-05-01 **Public Relations: How to Get the Message Out About Today's
Pharmacy Practice**
American Society of Health-System Pharmacists (ASHP)
Midyear Meeting
New Orleans, LA
- 12-04-01 **Serving as a Medical Expert Witness**
American Society of Health-System Pharmacists (ASHP)
2001 36th Annual Midyear Meeting
New Orleans, LA

- 11-18-01 **Diabetes Update: Alternative Delivery Devices**
Eckerd's Health Care
Southeastern Region Symposium
Bonita Springs, FL
- 11-06-01 **Billing for Clinical Services**
American Society of Clinical Pathologists (ASCP)
32nd Annual Meeting
Chicago, IL
- 08-09-01 **Collaboration is the Secret to Success**
Florida Society of Health-System Pharmacists (FSHP)
Annual Meeting
Orlando, FL
- 06-28-01 **FPA 111th Annual Meeting and Convention**
Marriott Marco Island Resort
Marco Island, FL
- 05-17-01 **New Drug Approvals and Research Pipelines**
Central Savannah River District of the Georgia Society of
Health-System Pharmacists
Martinez, GA
- 05-16-01 **Geriatric Practice: Pharmacy Consulting Models**
American Society of Consultant Pharmacists (ASCP)
23rd Midyear Conference 2001 Geriatrics Meeting
Washington, DC
- 05-05-01 **Getting Paid for your Services**
American Society of Consultant Pharmacists (ASCP)
23rd Midyear Conference
Washington, DC
- 03-25-01 **Handheld Medical Applications**
Florida Society of Health-System Pharmacists (FSHP)
2001 Spring Meeting, Health Professions Division, Nova
Southeastern University
Ft. Lauderdale, FL
- 03-01-01 **Update on Diabetes and Current Clinical Opportunities**
Association of Clinical Research Professionals (ACRP)
Suncoast Chapter
Tampa, FL
- 02-15-01 **Anti-infective Selection: The Impact Of Our Decisions**
Bayer
Tampa, FL
- 01-30-01 **Pharmacotherapy Update Insulin, Advances and Feature
NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Orlando, FL
- 01-23-01 **Diabetes Care and Clinical Research Update**
St. Joseph's Hospital, Institutional Review Board (IRB)
Tampa, FL

- 01-23-01 **Pharmacotherapy Update Insulin, Advances and Feature NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Publix Divisional Office
Marietta, GA
- 01-21-01 **Pharmacotherapy Update Insulin, Advances and Feature NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Gainesville, FL
- 01-18-01 **Pharmacotherapy Update Insulin, Advances and Feature NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Tampa, FL
- 01-14-01 **Pharmacotherapy Update Insulin, Advances and Feature NovoPen 3**
Diabetes Update Lectures for Publix Pharmacists, Novo Nordisk
Deerfield Beach, FL
- 12-08-00 **Legislative Update: Pharmacy Law and Current Initiatives**
American Society of Health-System Pharmacists
Public Relations Advisory Network
Midyear Clinical Meeting
Las Vegas, NV
- 10-02-00 **Managing the Pharmacy Benefit: We Must Strive to Improve Patient Care**
Pfizer - Tri-Service Forum Regions 3 & 4
Callaway Gardens, GA
- 05-26-00 **DUI Issues Training Seminar**
Hillsborough County Public Defender's Office
Tampa, FL
- 03-09-00 **Fluoroquinolone Update**
South Florida Society of Health System Pharmacists Meeting
Miami, FL
- 12-07-99 **Issues Surrounding Pharmacist Reimbursement**
American Society of Health-System Pharmacists (ASHP)
1999 Mid-Year Clinical Meeting
Orlando, FL
- 12-02-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Dallas, TX
- 12-01-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Houston, TX

- 11-02-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Baton Rouge, LA
- 10-25-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Meeting
Microbiology, Resistance and PK/PD of the Newer Agents
Ft. Worth, TX
- 09-29-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Bayer, The Pillars Restaurant
Mobile, AL
- 09-25-99 **Designing an Anticoagulation Clinic**
Saint Louis College of Pharmacy, St. Louis College of Medicine,
Fundamentals for Pharmaceutical Care Reimbursement
St. Louis, MO
- 09-23-99 **Antibiotic Selection in the Age of Resistance: A Focus on Newer Agents on Selected Respiratory Tract Infections**
Bayer - CME Dinner Conference
Microbiology, Resistance and PK/PD of the Newer Agents
Bayer, Donatello's Restaurant
Tampa, FL
- 08-13-99 **Getting Paid for Pharmaceutical Care: Guidelines for Medicaid, Medicare and Third Party Payer Reimbursement**
Pharmacy Society of Wisconsin (PSW)
1999 Annual Meeting
La Crosse, WI
- 03-05-99 **Long Term Care: Reimbursement for Clinical Services**
American Society of Consultant Pharmacists (ASCP)
North Carolina Chapter
Charlotte, NC
- 04-18-98 **Polypharmacy and the 20 Newest Drugs**
Nurse Practitioners Associates for Continuing Education
NPACE National Primary Care Conference
Orlando FL
- 03-03-98 **Advances in Quinolone Antibiotic Therapy**
Southern Gulf Society of Health-system Pharmacists
Ft. Myers, FL
- 02-24-98 **Overview of Quinolone Antibiotics: Current Market Trends**
Department of Pharmacy, St. Joseph's Hospital
Tampa, FL

- 02-20-98 **Establishing, Documenting & Marketing Clinical Services**
Clinical Practice in a Managed Care Era
22nd Annual Clinical Pharmacy Symposium
Florida A&M University School of Pharmacy
Tallahassee, FL
- 01-27-98 **Pharmaceutical Care Services in the Long Term Care Setting:
Reimbursement Strategies**
Clinical Advisory Board
Omnicare International
Cincinnati, OH
- 11-15-97 **Compensation Strategies for Hyperlipidemia Programs**
Hyperlipidemia Conference '97
Auburn University, School of Pharmacy
Auburn, AL
- 11-11-97 **Biotechnology: Pharmaceutical Care Practice Opportunities**
University of Illinois at Chicago, College of Pharmacy
Symposium on Biotechnology
Chicago, IL
- 10-18-97 **Managed Care: Drug Formulary Strategies**
Managed Care Success Strategies, Tampa Westin Hotel
Tampa, FL
- 09-27-97 **Embracing Pharmaceutical Care Practices**
Southern California Society of Health-systems Pharmacists
Los Angeles, CA
- 09-17-97 **Biotechnology: Pharmaceutical Care Practice Opportunities**
Chicago, IL
- 09-09-97 **Update on Reimbursement Strategies for Pharmaceutical Care
Services**
University of Florida Law & Management Conference
Orlando, FL
- 08-26-97 **Development of Clinical Pharmacy Services and Practice
Management Systems**
VHA Conference, Opryland Hotel
Nashville, TN
- 08-02-97 **Reimbursement Strategies for Clinical Services for Managing
Patients with Osteoporosis**
Osteoporosis Treatment Management
Mercer University
Atlanta, GA
- 07-11-97 **Asthma: Treatment and Therapeutic Alternatives**
Establishing Patient Care Services in the Pharmacy: The Basics,
CarePoint
Atlanta, GA
- 06-27-97 **Osteoporosis & Reimbursement**
Mercer University
Atlanta, GA

- 06-20-97 **Developing Advanced Practice Models for Pharmaceutical Care Services**
Pennsylvania Society of Health-System Pharmacists
Long Branch, NJ
- 06-07-97 **Developing Reimbursement Strategies for Ambulatory Care Services**
Nebraska Pharmacists Association
1997 Annual Convention
Grand Island, NE
- 05-17-97 **Pharmacists-based Clinical Pharmacology Research**
Florida Society of Health-Systems Pharmacists
1997 Annual Meeting
Ft. Lauderdale, FL
- 05-16-97 **Reimbursement for Pharmaceutical Care: Present and Future Considerations**
Pharmaceutical Care A Closer Look, North Carolina Council on Pharmaceutical Care
Chapel Hill, NC
- 05-16-97 **Marketing Pharmaceutical Care: An Essential Ingredient**
Pharmaceutical Care A Closer Look
North Carolina Council on Pharmaceutical Care
Chapel Hill, NC
- 05-10-97 **New Horizons in Diabetes Management: Reimbursement Models**
New Jersey Society of Certified Diabetes Education
Diabetes Educators Symposium
Voorhees, NJ
- 05-03-97 **Practice models for service and reimbursement – Diabetes Management**
Metro New York – Garden State Diabetes Educators Symposium
West Orange, NJ
- 05-01-97 **Evaluation Methods for Clinical Pharmacology Trials**
University of South Florida, Department of Pediatrics
Residents Program
Tampa, FL
- 04-29-97 **Tinnitus: Treatment and Management Update**
American Tinnitus Association
Tampa Bay Chapter/Support Group
Tampa, FL
- 04-22-97 **Clinical Pharmacology Review: American Board of Internal Medicine Review Course**
University of South Florida College of Medicine
Medical Residents
Tampa, FL
- 04-12-97 **Advanced Practice Models: The Future of Pharmaceutical Care**
Louisiana Society of Health-System Pharmacists
New Orleans, LA

- 04-04-97 **New Treatments for HIV: Update**
National Association of Nurse Practitioner's Conference
1997 NPACE
Orlando, FL
- 04-04-97 **Top 20 New Medications**
National Association of Nurse Practitioner's Conference
1997 NPACE
Orlando, FL
- 04-04-97 **Antibiotic Update: 1997**
National Association of Nurse Practitioner's Conference
1997 NPACE
Orlando, FL
- 03-15-97 **Advanced Practice Models for Pharmaceutical Care**
South Florida Society of Health-System Pharmacists
Miami, FL
- 03-09-97 **Developing Reimbursement Strategies for Clinical Pharmacy Services**
Greensboro AHEC
Greensboro, NC
- 03-07-97 **Getting Paid for Pharmaceutical Care: Reimbursement Workshop**
American Pharmaceutical Association (APhA)
1997 Annual Meeting
Los Angeles, CA
- 12-12-96 **Cost Impact of Lipid Lowering Therapy**
Managed Care Medical Directors of Florida
1996 Annual Meeting
Tampa, FL
- 09-14-96 **Management of Tuberculosis: Clinical Case Studies**
Southwest Florida Society of Health system Pharmacists (SWFSHP)
1996 Annual Meeting
Update on the Management of Infectious Diseases
Tampa, FL
- 11-07-96 **Value of Pharmaceutical Disease Management in Reducing Overall Health Care Costs**
Merck - Central Florida Health Care Coalition (CFHCC)
Orlando, FL
- 08-17-96 **Management and New Therapies for HIV Infection**
Update on HIV and Related Infections
A Continuing Education Program for Pharmacists
University of South Florida
Tampa FL
- 04-08-96 **Implementation of Community Based Pharmaceutical Care Service**
Florida Society of Health-System Pharmacists Midyear Meeting
Ft. Lauderdale, FL

- 03-26-96 **Newer Antibiotics in the Managed Care Setting**
Challenges in Pharmaceutical Care
Braintree, MA
- 02-22-96 **Pharmacokinetic Services: Pharmacist Managed Consult Service Model**
Polk County Pharmaceutical Association
Bartow, FL
- 02-10-96 **Pharmacoeconomic Trials: Designing Research Trials to Improve Clinical Outcomes and Reduce Health Care Costs**
United States Pharmacoeconomic Advisory Board, Bayer
Vail, CO
- 11-07-95 **Value of Pharmaceutical Disease Management In Reducing Overall Health Care Costs Reducing Overall Health Care Costs Through Pharmaceutical and Disease Intervention,**
The Healthcare Revolution, Central Florida Health Care Coalition (CFHCC)
Orlando, FL
- 10-04-95 **Pharmacy Management Course**
University of Florida
Gainesville, FL
- 10-01-95 **Applying Reimbursement Coding to Pharmaceutical Care Services**
New York State Council of Health-System Pharmacists
1995 Annual Meeting
Newburgh, NY
- 09-16-95 **Pharmacists Care of Anticoagulant and Cardiovascular Patients**
Florida Pharmacy Association Continuing Education Series
St. Petersburg, FL
- 08-26-95 **Practical Issues Related to the Conduct of Clinical Trials, Research & Development: Oral Streptogramins In Sinusitis**
Four Seasons Hotel
Chicago, IL
- 08-15-95 **Expanding Services in the Diabetes Marketplace**
Orange County Pharmaceutical Association
Orlando, FL
- 08-07-95 **Macrolide Antibiotic Update**
American College of Clinical Pharmacy
1995 Annual Meeting
Washington, DC
- 08-04-95 **Pharmaceutical Care: Nephrology Services, Developing Reimbursement Strategies**
Florida Society of Health-system Pharmacist
1995 Annual Meeting, Stouffer Hotel
Orlando, FL

- 08-04-95 **Justification of Pharmacy Services: Survival for the Future, Panel Discussion**
Opening Session, Florida Society of Health-system Pharmacist
1995 Annual Meeting, Stouffer, Hotel
Orlando, FL
- 07-25-95 **Implementing Pharmaceutical Care**
Practitioner Panel Tennessee Pharmacist Association 108th
Annual Meeting
Memphis, TN
- 06-06-95 **Expanding Pharmaceutical Care in and Era of Declining Resources**
American Society of Hospital Pharmacists
1995 Annual Meeting
Philadelphia, PA
- 05-21-95 **Issues in Infectious Diseases: 1995**
CE on the SEA, Continuing Education Seminar
Ocho Rios, Jamaica
- 05-19-95 **Antibiotic Update: 1995**
Florida Nurses Association, Belleview Biltmore
Clearwater, FL
- 05-16-95 **Update on Antifungal Therapy: Primer for Clinical Practice**
Pinellas County Pharmaceutical Association
Pinellas Park, FL
- 05-10-95 **Steroid Overview for Primary Care Practice**
Nurse Practitioner Association for Continuing Education
1995 Annual Meeting
Orlando, FL
- 04-18-95 **Pharmaceutical Care: Intensive Insulin Therapy**
Southern Gulf Society of Hospital Pharmacist, Holiday Inn
Ft. Myers, FL
- 04-08-95 **Pharmacotherapeutic Care Plans for Ambulatory Patients**
Implementation of Community Based Pharmaceutical Care
Service
Ft. Lauderdale, FL
- 04-08-95 **Developing a Nephrology Pharmaceutical Care Practice**
Florida Society of Hospital Pharmacist
1995 Annual Meeting
Ft. Lauderdale, FL
- 04-07-95 **Issues and Advances in Pediatrics. Advances in Pediatric Pharmacology: Medications and Drug Delivery Systems**
Sheraton Sand Key Resort
Clearwater Beach, FL
- 03-21-95 **Reimbursement for Pharmaceutical Care Services**
Southern Gulf Society of Hospital Pharmacist
Lee Memorial Hospital
Ft. Myers, FL

- 02-16-95 **Early Presumptive Antifungal Therapy**
Internal Medicine Grand Rounds, University of South Florida
College of Medicine
Tampa, FL
- 02-24-95 **Aminoglycoside and Vancomycin Pharmacokinetics: Clinical Application**
Course# PHA4123/5121, University of Florida, College of Pharmacy
Gainesville, FL
- 02-25-95 **Pediatric Hyperlipidemia: Assessment and Management**
University of Florida College of Pharmacy
Post Graduate PharmD. Program, USF College of Public Health
Tampa, FL
- 02-04-95 **New Approaches to Cancer Therapy: Gene Therapy and Monoclonal Antibodies**
Florida Pharmacy Association
Academy of Pharmacy Practice
Clinical Mid-Year Conference
Orlando, FL
- 01-27-95 **Reimbursement Factors in Modern Healthcare**
Miles 1995 Pharmacy Advisory Board
Innisbrook, FL
- 01-28-94 **Pharmaceutical Care and Reimbursement for Pharmacy Services**
Miles Pharmacy Advisory Group
Tarpon Springs, FL
- 12-13-94 **Establishing Reimbursement Guidelines for Cognitive Services**
North Pinellas Pharmacy Association
Tarpon Springs, FL
- 12-05-94 **Issues in Antifungal Therapy**
American Society of Hospital Pharmacists
Exhibitor's Theater Program
29th Midyear Clinical Meeting, Miami Beach Convention Center
Miami, FL
- 11-19-94 **Clinical Aspects of Early Antifungal Therapy in the ICU**
Cost Effectiveness in the ICU
Orlando Hilton
Orlando, FL
- 11-10-94 **Review of Antifungal Therapy**
Mobile Pharmacy Association, Providence Hospital
Mobile, AL
- 10-18-94 **Diabetes and the Geriatric Patient**
VA Medical Center
Miami, FL

- 10-07-94 **Medications and Their Impact on Ototoxicity and Patient Assessment**
Florida Speech and Hearing Association
1994 Annual Meeting
Cocoa Beach, FL
- 10-06-94 **Contribution of Biotechnology to Pharmaceutical Pipelines: Current and Future**
American College of Clinical Pharmacology, Symposium
23rd Annual Meeting
Orlando, FL
- 08-05-94 **Obtaining Reimbursement for Therapeutic Outcomes Monitoring**
TOM Pharmacist Meeting
University of Florida College of Pharmacy
Gainesville, FL
- 08-04-94 **Considerations in the Diagnosis and Treatment of Fungal Infections**
National Teleconference, American Teleconferencing
Tampa, FL
- 08-04-94 **A Pharmacotherapeutic Care Plan Model: Renal Disease, Pharmacoeconomic Considerations II**
Florida Society of Health system Pharmacists
1995 Annual Meeting
Orlando, FL
- 08-04-94 **Financial Impact of Innovative Pharmaceutical Services**
Florida Society of Health system Pharmacists
Opening General Session: Forces Affecting Health Care in Florida
1995 Annual Meeting
Orlando, FL
- 07-08-94 **Reimbursement for Pharmacy Services**
Arizona Society of Hospital Pharmacists
1994 Annual Meeting
Tucson, AZ
- 06-22-94 **Antifungal Therapy: Clinical Software Applications**
Pharmacy Grand Rounds, Gunnersville Hospital
Gunnersville, AL
- 06-21-94 **Antifungal Therapy: Clinical Software Applications**
University Hospital Pharmacists
Birmingham, AL
- 06-20-94 **Rational Antifungal Therapy in Hospitalized Patients**
Grand Rounds, Lakeland Regional Hospital
Lakeland, FL
- 06-08-94 **Pain Management and Non-steroidal Anti-inflammatory Agents**
Pain Management Symposium, Tampa General Hospital
Tampa, FL

- 06-07-94 **Maximizing Reimbursement for Pharmaceutical Products and Services**
American Society of Hospital Pharmacists, Exhibitor's Theater,
51st Annual Meeting
Reno, NV
- 05-05-94 **The Rising Cost of Candida Infections**
Northwest Alabama Pharmacists Association
Florence, AL
- 04-08-94 **Antifungal Therapy in the Critically Ill**
American Association of Critical Care Nurses Gulf coast
Chapter Spring Meeting
- 03-26-94 **Reimbursement Guidelines for Pharmacy Services**
Pharmaceutical Care Forum, CarePoint
Folly Beach, SC
- 03-06-94 **Health Care Reform: Preparing Pharmacy for Change**
Tennessee Society for Hospital Pharmacist
1994 Annual Meeting
Nashville, TN
- 02-25-94 **Patient Education and Pharmaceutical Care**
1994 Update: Colony Stimulating Factors
St. Petersburg, FL
- 02-15-94 **Opportunities for Pharmacists in Biotechnology**
West Alabama Society of Hospital Pharmacists
Tuscaloosa, AL
- 02-10-94 **Health care Reform: It's Impact on Pharmacy Practice**
Society of Hospital Pharmacists
Tallahassee, FL
- 02-05-94 **Patient Monitoring - Software Applications**
Cytokine Forum Group
San Diego, CA
- 02-04-94 **Developing Reimbursement Guidelines of Pharmaceutical Care Services**
CarePoint Pharmaceutical Care Conference
Atlanta, GA
- 01-28-94 **Pharmaceutical Care and Reimbursement for Pharmacy Services**
Miles Pharmacy Advisory Group
Tarpon Springs, FL
- 01-13-94 **Implementing System for Payment**
An update on OBRA 90
The 22nd Annual Pharmacy Law and Management
Conference
Lake Buena Vista, FL
- 12-09-93 **New Clinical Software Applications**
American Society of Hospital Pharmacists
1993 Midyear Clinical Meeting
Atlanta, GA

- 12-09-93 **Clinical Case Studies: Antifungal Therapy**
American Society of Hospital Pharmacists
1993 Midyear Clinical Meeting
Atlanta, GA
- 12-08-93 **Health Care Reform: It's Impact on Hospitals and Pharmacy,
How Hospital Pharmacy Will Be Affected**
American Society of Hospital Pharmacists
1993 Midyear Clinical Meeting
Atlanta, GA
- 11-21-93 **Biotechnology Pharmaceutical Products: The Pharmacists Role**
South Dakota Pharmaceutical Association
1993 Annual Meeting
Sioux Falls, SD
- 11-13-93 **Implementing a System for Payment**
University of Florida College of Pharmacy
22nd Annual Pharmacy Law and Management Conference,
"An Update of OBRA 90"
Gainesville, FL
- 11-12-93 **The Diabetes Marketplace**
Gulf Coast Pharmaceutical Association
Ft. Meyers, FL
- 11-07-93 **Pharmacoeconomics and Colony Stimulating Factors**
Georgia Society of Hospital Pharmacists
Thomasville, GA
- 10-03-93 **Reimbursement for Patient Consultation**
Illinois Pharmacists Association
113th Annual Meeting and Exhibition
Rockford, IL
- 09-26-93 **Insulin & Diabetes Update**
Southeastern Society of Hospital Pharmacists
Ft. Lauderdale, FL
- 09-14-93 **Update on Health Care Reform**
Eastern Shores Florida Society of Hospital Pharmacists
Daytona, FL
- 08-22-93 **Experiences with Utilization of CPT Coding Reimbursement for
Clinical Services: Round Table Forum**
Florida Society of Hospital Pharmacists
1993 Annual Meeting
Orlando, FL
- 08-19-93 **Managing Patients on Biologic Response Modifiers Practical
Applications of Biologic Response Modifiers**
Florida Society of Hospital Pharmacists
1993 Midyear Meeting
Orlando, FL
- 08-14-93 **Leadership Skills: Tricks of the Trade**
Florida A&M Leadership Conference
Orlando, FL

- 07-13-93 **The Pharmacoeconomics of Antifungal Therapy**
Vanderbilt University, Department of Pharmacy
Nashville, TN
- 07-10-93 **Pharmaceutical Biotechnology Update**
ALCO Health Services Corporation
1993 Annual Meeting
Orlando, FL
- 06-24-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Teleconference Pfizer Pharmaceuticals
- 06-22-93 **Insulin Update**
Hillsborough County Pharmaceutical Association
Tampa, FL
- 06-10-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Teleconference Pfizer Pharmaceuticals
Tampa, FL
- 06-07-93 **Amlodipine and Beta Blockers**
American Society of Hospital Pharmacists
1993 Annual Meeting
Denver, CO
- 05-30-93 **Developing Reimbursement Strategies for Clinical Services**
Florida A&M University
Clearwater, FL
- 05-25-93 **Monitoring Patients on Biologic Response Modifiers**
National Home Infusion Association/National Association of
Retail Druggist
1993 Annual Meeting, Rx Expo '93
Orlando, FL
- 05-21-93 **Clinical Pharmacokinetic Software**
University of Florida, Applied Pharmacokinetics 1993
Gainesville, FL
- 05-19-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Teleconference Pfizer Pharmaceuticals
Tampa, FL
- 05-13-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Capital Society of Hospital Pharmacists
Tallahassee, FL
- 05-07-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Flagler Community Hospital, Department of Pharmacy
St. Augustine, FL
- 05-07-93 **Important Issues in the Selection of IV versus PO Fluconazole**
St. Vincent's Hospital, Department of Pharmacy
Jacksonville, FL

- 05-01-93 **Drug Research and Development: From the Laboratory to the Drug Store**
Cystic Fibrosis Family Day, University of South Florida,
Department of Pediatrics
Tampa, FL
- 04-29-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Teleconference Pfizer Pharmaceuticals
Tampa, FL
- 04-28-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Birmingham Hospital Pharmacists Program
Birmingham, AL
- 04-27-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Montgomery Regional Hospital Pharmacists, Penach at
Rose Hill
Montgomery, AL
- 04-23-93 **Pharmaceutical Biotechnology Update**
American Association Critical Care Nurses
1993 Annual Meeting
Clearwater, FL
- 04-22-93 **Pharmaceutical Biotechnology: Research and Development**
Anderson Memorial Hospital, Medical Grand Rounds
Anderson, SC
- 04-07-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Teleconference Pfizer Pharmaceuticals
Tampa, FL
- 02-24-93 **Important Issues in the Selection of IV versus PO Fluconazole**
Teleconference Pfizer Pharmaceuticals
Tampa, FL
- 02-18-93 **Therapeutic Drug Monitoring: Antibiotics**
University of Florida, College of Pharmacy
Pharmacokinetics Course
Gainesville, FL
- 12-28-92 **JCAHO and Home Health Care**
CareStat of Colorado, Department of Pharmacy
Denver, CO
- 12-15-92 **Selection of IV versus PO Fluconazole Therapy**
Teleconference
Tampa, FL
- 12-13-92 **Reimbursement for Clinical Pharmacy Services**
Florida Pharmaceutical Association
Sarasota, FL
- 11-21-92 **Reimbursement for Clinical Pharmacy Services "Implementing OBRA '90"**
Twenty-First Annual Pharmacy Law and Management
Conference
Orlando, FL

- 11-20-92 **Pharmacy Practice in the 1990's**
Seminole Heights Elementary School, Great American Teach-In
Tampa, FL
- 10-24-92 **New Medications and Absorption Routes - How They Can Interact**
Florida Nurses Association
Third Annual Pharmacology Update
Tampa, FL
- 10-14-92 **Drug Utilization Review and Outcomes Management**
Georgia Shared Services, Fall Forum 1992
Callaway, GA
- 10-07-92 **Pharmacological Approach to the Treatment of Pressure Ulcers**
Pressure Ulcers - Prevention, Assessment, Treatment and Infection Control
Sand Key Beach, FL
- 09-30-92 **Review of Antifungal Therapy**
Pfizer Pharmaceuticals, Southeastern Regional Sales Division
Regional Sales Meeting
Tampa, FL
- 09-15-92 **Advances in Oral Antibiotics**
Augusta Pharmaceutical Association
Augusta, GA
- 09-06-92 **Biotechnology and Immunology**
Puerto Rico Pharmaceutical Association
San Juan, Puerto Rico
- 08-14-92 **Biotechnology and Drug Development**
Pharmacy Grand Rounds
HCA Community Hospital
New Port Richey, FL
- 08-13-92 **Review of Amphotericin B and Antifungal Therapy**
Roche Professional Services Division
Home Health Pharmacy Services
Tampa, FL
- 07-27-92 **Advances in Biotechnology and Drug Development**
Pharmacy Grand Rounds, St. Joseph's Hospital
Tampa, FL
- 07-18-92 **Application of Biotechnology in Medicine**
Florida Pharmaceutical Association, Annual Meeting 1992,
Boca Raton, FL
- 07-14-92 **Advances in Hospital Pharmacy Practice**
Pharmaceutical Training Seminar, Miles, Inc.
Orlando, FL
- 05-20-92 **Health Care Reform: Impact on Pharmacy Services**
Eastern Shores Society of Hospital Pharmacists
Daytona Beach, FL

- 05-15-92 **All Americas Health care Conference**
AIDS Update, Moderator
Tampa, FL
- 04-16-92 **Antimicrobial Testing and Resistance**
Memorial Hospital (AMI)
Tampa, FL
- 04-14-92 **Clinical Pharmacology Review of Sertraline**
Hillsborough County Pharmaceutical Association
Tampa, FL
- 04-02-92 **Monoclonal Antibodies and Antibiotic Selection**
Pinellas County Hospital Pharmacists
Clearwater, FL
- 03-25-92 **Monoclonal Antibodies: Clinical Applications**
Health care Forum, Regional Hospital Consortium
Miami, FL
- 03-11-92 **Biotechnology in Retail Pharmacy**
Pasco/Hernando County Pharmaceutical Association
New Port Richey, FL
- 03-05-92 **Introduction to Use and Handling of Biotechnology Agents**
Ohio Society of Hospital Pharmacists, "Pharmacy Technician
Program"
1992 Annual Meeting
Dayton, OH
- 02-27-92 **Introduction to Clinical Pharmacology Principles**
University of South Florida, Internal Medicine Noon Conference
Tampa, FL
- 02-05-92 **Therapeutic Drug Monitoring in Psychiatry**
University of South Florida, Psychiatry Residence Conference
Tampa, FL
- 01-15-92 **Analysis of Antibiotic Selection and Treatment on the Clinical
Outcome of Monoclonal Anti-Endotoxin Therapy**
Merck Research Laboratories
Rahway, NJ
- 12-10-91 **Profile of the Clinical Pharmacokinetic Software Marketplace**
Syva International, Marketing Division
Tampa, FL
- 12-05-91 **Selecting Clinical Pharmacokinetic Software**
American Society of Hospital Pharmacists
1991 Midyear Clinical Meeting
New Orleans, LA
- 12-01-91 **Clinical Applications for Colony Stimulating Factors**
Long Island Hospital Pharmacy Directors Meeting
Long Island, NY
- 09-29-91 **Clinical Documentation: Important or Impractical?**
Indian River Pharmacy Association
Vero Beach, FL

- 08-10-91 **Colony Stimulating Factors: From Laboratory to Clinical Applications**
Southern Gulf Society of Hospital Pharmacist
Ft. Myers, FL
- 08-08-91 **Medical Legal Issues in Pharmacy Practice**
Moderator Current Issues in Pharmacy Practice
Lake Buena Vista, FL
- 06-07-91 **Colony Stimulating Factors: Clinical Applications**
Southeastern Society of Hospital Pharmacists
North Broward Medical Center
Ft. Lauderdale, FL
- 05-16-91 **Colony Stimulating Factors: From Laboratory to Clinical Applications**
Polk County Pharmacy Association
Lakeland, FL
- 04-26-91 **Evaluation of Clinical Services: Outcomes Management**
Moses H. Cone Hospital, Pharmacy Grand Rounds
Greensboro, NC
- 04-06-91 **Clinical Impact of Nutrition Support in Home Health care**
Roche Professional Services, Clinical Training Program
Tampa, FL
- 03-15-91 **Therapeutic Drug Monitoring: Applications in Home Health care**
Dun & Bradstreet Corporation
Tampa, FL
- 01-26-91 **Pharmacology Concerns for the Audiologist**
Florida Association of Speech, Hearing, and Audiology
(FLASHA) Winter Conference
Gainesville, FL
- 01-19-91 **Drug-Induced Ototoxicity**
Florida Language Speech and Hearing Association
1991 Winter Meeting
Cocoa Beach, FL
- 11-90 **Clinical Outcomes Management**
Southwest Florida Society of Hospital Pharmacists
1990 Annual Meeting
St. Petersburg, FL
- 08-90 **Clinical Pharmacokinetics: Software Review**
Florida Society of Hospital Pharmacists
24th Annual Meeting
Orlando, FL
- 06-90 **Outcomes Management**
Southwest Central Louisiana Society of Hospital Pharmacists
Baton Rouge, LA
- 05-90 **Anti-Infective Therapy in the Immunocompromised Patient**
Orlando Pharmacy Symposium '90, Co-Chairman
Orlando, FL

- 10-89 **Review of Clinical Pharmacokinetic Software**
 California Society of Hospital Pharmacists Seminar
 1989 Meeting
 Los Angeles, CA
- 10-89 **Evaluation of Commercially Available Pharmacokinetic Software Systems**
 Georgia Society of Hospital Pharmacists Midyear Meeting
 Athens, GA
- 10-89 **Bayesian Pharmacokinetics**
 Pharmacy Grand Rounds, H. Lee Moffitt Cancer Center
 Tampa, FL
- 02-89 **Clinical Pharmacokinetics Software Systems**
 Pharmacy Grand Rounds, H. Lee Moffitt Cancer Center
 Tampa, FL
- 04-88 **Design and Implementation of a Computerized Pharmacokinetic Patient Tracking System**
 Southeastern Residents Conference
 Athens, GA
- 10-87 **Geriatric Pharmacology: Therapeutic Considerations**
 Emory University Hospital, Pharmacy Grand Rounds
 Atlanta, GA
- 11-86 **Aminoglycoside Dosing Adjustments in Renal Failure**
 Emory University Hospital, Clinical Pharmacy Department
 Atlanta, GA
- 08-86 **Vaccinating the Elderly**
 Veteran's Administration Hospital, Medical Staff
 Atlanta, GA
- 06-86 **Pneumocystis carinii Pneumonia in AIDS Patients: Current Treatments and Investigational Agents**
 Dekalb General Hospital, Clinical Pharmacy Department
 Atlanta, GA
- 11-85 **The Pharmacological Interactions of Lithium Carbonate**
 Georgia Mental Health Institute, Medical Staff Conference
 Atlanta, GA
- 11-85 **Clinical Case Study: Organic Personality Syndrome**
 Georgia Mental Health Institute, Medical Staff Conference
 Atlanta, GA

TELEVISION / RADIO / MEDIA:

- 05-01-13 **Transitional Care CPT Codes May Include Pharmacists' Services**
 Pharmacy News
 Kate Traynor
- 09-11-12 **Connecting Health: Medication Therapy Management**
 Medical Update Show
 Jacksonville, FL

01-14-10 **Antidepressants Can Lead to Weight Gain**
St. Petersburg Times
Irene Maher

10-09 **Current Concepts in Pharmacy Management: Medicare Part D**
Interview
David's Production, Inc.

07-09-09 **United States Health Care Reform 2009**
Drive Time with Bill Bunkley, WTNB
William Bunkley

07-09 **Viagra – Video Taped Interview**
Posted on website

06-24-09 **Increased abuse of synthetic medications**
BBC World News: World Service
George Arney

08-18-08 **Opiate Toxicity**
Dr. G Medical Examiner Show
Discovery Health

10 – 07 **Front-line Practitioners Offer Keys To Their Success**
Pharmacy Today
Page 36

07-21-07 **Tampabay.com Know it now**
An Hour of Expert Witness Time, \$4,000
Interview with Scott Barancik

06-01-06 **Pharmacist Current Procedural Terminology Codes and**
Medication Therapy Management
American Journal of Health-System Pharmacists
Volume 63, Page 1008 & 1010

05-09-06 **Medicare Part D: The Facts about the May 15th Deadline for**
Signing up
Drive Time, WTNB AM 570/910, News Radio

04-12-06 **Medicare Part D: Selecting the Plan That Meets Your Needs**
Drive Time, WTNB AM 570/910, News Radio

09-07-05 Linda Hurtado, Channel 28

07-19-05 **Medication Importation and Risk of Fatal Toxicities**
Dr. G Medical Examiner (Jan C. Garavaglia, MD)
Discovery Health Channel

07-13-05 **Post Partum Depression**
Channel 13, WTVT/FOX, Kathy Fountain Show,
Tampa, FL

05-01-05 **Distinguished Achievement Award in**
Clinical/Pharmacotherapeutic Practice
APhA – APPM awardees to be recognized APhA2005
Annual Meeting News

01-25-05 **Jeff Fisher (WFLA-AM) Interview**
Tampa, FL

- 02-24-04 **Violence In 'Passion' Necessary, Viewers Say**
The Tampa Tribune, Metro, Philip Morgan
- 02-01-04 **APhA Member Goes to Bat for Pharmacy**
Pharmacy Today, Volume 10, Number 2
- 12-03 **People Talk - Daniel E. Buffington, PharmD, MBA a Member of The X12 Panel**
Computer Talk, Volume 23, Number 6, November/December 2003, Page 51
- 06-03 **What You Can Do: Tips for Telling Your Story**
ASHP Action Line, Special Edition, The American Society of Health-System Pharmacists, Monthly New Bulletin, Volume 33, Number 3
- 01-03 **Beyond dispensing and drug therapy management: Pharmacist creates a medical specialty practice model**
APHA Pharmacy Today, Volume 9, Number 1, January 2003, Pages 14-15, 18
- 01-10-02 **Experts: Safe overall, drug demands caution**
St. Petersburg Times, Newspaper
- 06-20-01 **Oxycontin**
Channel 62, WVEA-TV (Entravision), Evening News, Tampa, FL
- 10-06-00 **Drug Pricing**
Channel 8, WFLA, Evening News, Tampa, FL
- Summer 2000 **Innovative Pharmacology Practice Decreases Healthcare Costs**
Health & Medical Feeling Good, Summer 2000, Page 27-28
- 02-09-98 **Golf Max**
CBS Channel 10, WTSP, Evening News, Tampa, FL
- 01-30-98 **Cleaning Out Your Medicine Cabinet**
Channel 8, WFLA, Evening News, Tampa, FL
- 10-13-97 **Nutritional Supplements: Trends in Alternatives to Prescription Medications**
Channel 10, WTSP/ACB, Evening News, Tampa, FL
- 06-30-97 **Non-prescription Products for Relief of Alcohol Related Hangovers**
Channel 10, WTSP/ACB, Evening News, Tampa, FL
- 06-18-97 **Caffeine Containing Soft Drinks and their Impact on Your Health**
Channel 8 WFLA, NBC Evening News, Tampa, FL
- 04-28-97 **Understanding Prescription Medication Pricing**
Channel 10, WTSP/ABC News, Tampa, FL

02-25-97 **Oral Contraceptives: Morning After Pills?**
Channel 8, WFLA, NBC Evening News,
Tampa, FL

01-28-97 **Breast Pill**
Channel 10, WTSP News,
Tampa, FL

11-28-96 **Diabetes: Understanding New Drug Therapies**
Channel 28, WFTS/ABC, Evening News
Tampa, FL

11-11-96 **Medications which may cause weight gain**
Channel 8, WFLA, NBC Evening News,
Tampa, FL

11-05-96 **Nutritional Supplements for Sports & Fitness: Helpful or Harmful**
Channel 28, WFTS/ABC, Evening News,
Tampa, FL

09-23-96 **HIV Treatment Update: Salk/Remune Vaccine**
Channel 13, WTVT/FOX, Good Morning Tampa Bay,
Tampa, FL

09-13-96 **Dr. On Call, What is Remune?**
Channel 13,
Tampa, FL

09-09-96 **New Experimental Vaccine Therapy for HIV**
Channel 8, WFLA/NBC, Evening News,
Tampa, FL

1996 **Clinical Pharmacology Services – Medication Consulting &
Clinical Research**
Feeling Good, Premiere Issue 1996, Page 39

08-29-96 **Developing New Treatments for HIV & AIDS Infection**
Channel 8, WFLA, NBC Evening News,
Tampa, FL

02-07-96 **Smoking Cessation: Using Injectable Medications**
Channel 8, WFLA/NBC, Evening News,
Tampa, FL

11-07-95 **Analgesics**
Channel 13,
Tampa, FL


10-10-95 **Medications in the Treatment of Obesity**
Channel 13 WTVT, Evening News,
Tampa, FL

09-14-95 **Non-approved use of prescription medications: Misoprostol and
Methotrexate**
Channel 13, WTVT, FOX, Evening News,
Tampa, FL

- 08-24-95 **Medications in the Elderly: United States General Accounting Office 1995 Report**
Channel 13, WTVT, FOX, Good Morning Tampa Bay,
Tampa, FL
- 08-23-95 **GATT Treaty and it's Impact on Pharmaceutical Patents and Pricing**
National Public Radio (NPR), WUSF 90 FM,
Tampa, FL
- 07-27-95 **Prescription to over-the-counter antacid preparations**
Channel 13, WTVT/FOX, Good Morning Tampa Bay,
Tampa, FL
- 06-13-95 **Diet Pills and Weight Loss**
Channel 13, WTVT/CBS, Evening News
Tampa, FL,
- 02-22-95 **Overmedication in The Elderly**
Channel 8, WFLA/NBC News, Evening News,
Tampa, FL
- 11-01-94 **Awards and Installation Banquet, FSHP Forerunner Award**
The Florida Journal of Hospital Pharmacy, Volume 14 Number 5,
- 05-19-94 **Medical Charity Concert - Band Side FX**
Channel 8, WFLA, NBC, Evening News,
Tampa, FL
- 05-04-94 **Antibiotic Resistance**
Channel 8, WFLA, NBC, Evening News,
Tampa, FL
- 04-13-94 **Toxic Effects of Tobacco and Solvents Used in the Production of Cigarettes**
Channel 10, WTSP, ABC, Evening News,
Tampa, FL
- 02-15-94 **Health Tips: Medication Awareness and Counseling**
Channel 8, WFLA, NBC, Evening News,
Tampa, FL
- 06-30-93 **Cow's Head Pills: Asian Herbal Medications**
Channel 13, WTVT, CBS, Morning News,
Tampa, FL
- 03-25-93 **New Medical Uses for Aspirin**
Channel 8, WFLA, NBC, Morning News
Tampa, FL

Exhibit 4

FITSNEN'S



CLINICAL PHARMACOLOGY SERVICES

February 20, 2025

Shaun Kent, Esq
Kent Law Firm
19 S Mill St
Manning, SC 29102

Alexandra Benevento, Esq
Strom Law Firm
6923 North Trenholm Road, Suite 200
Columbia, SC 29206

RE: State of South Carolina v Zachary Elias

Dear Counsels:

I have received and reviewed the records provided to me pertaining to the case of State of South Carolina v Zachary Elias. The information incorporated into my review includes the toxicology reports prepared by the South Carolina Law Enforcement Division (SLED), specifically 01/17/25 and 02/06/25, which include the drug screen reports for the oral "mushroom products" products consumed by Zachary Elias and his blood obtained on following the incident on 12/04/24. These results were subsequently verified by the SLED forensic staff; Shana B. Sorrells and Quintus Young, II, respectively. In addition, I conducted an onsite clinical evaluation of Zachary Elias at the York County Detention Center within the Moss Justice Center in Rock Hill, SC on 12/30/24.

I have been retained to assist the court in evaluating the pharmacology and toxicology aspects of this case, specifically regarding commercially available over-the-counter medications sold to and consumed by Zachary Elias and the pharmacologic substances identified within his blood stream. Additionally, I will assist with other related technical and medical questions.

Background

This information was provided by interview with the client and is subject to change after a full and thorough review after discovery. Zachary Elias is a 28-year-old male with no significant past medical or criminal history. He resides in South Carolina and is employed in a high-stress, performance-driven occupation. As part of his routine, he occasionally used CBD gummies and Delta-8 THC vape pens for relaxation and sleep. On 12/02/24 (Monday) after work, he visited Budiman's Smoke Shop located in Rock Hill, SC intending to purchase his usual CBD product. He had been accustomed to taking CBD gummies as a sleep aid with no complaints of side effects or unexpected psychiatric complications. However, the store staff informed him that his preferred CBD product was out of stock and suggested an alternative. The sales representative recommended a "Magic Mushroom Chocolate" bar manufactured by Silly Farms, Inc. (<https://sillyfarms.co/>). Zachary Elias purchased one (1) "Wavy Wafer Magic Mushroom Chocolate" bar and consumed a small portion (approximately 2 squares) of the product that evening. He reported no perceived benefits or adverse side effects after consumption.



(813) 983-1500 Clinic
(813) 983-1501 Fax



www.cpshealth.com
info@cpshealth.com



6285 E Fowler Ave
Tampa, Florida 33717



Front



Back

Two days later, on 12/04/24, he returned to the store to check for the CBD gummies he regularly used, but they were out of stock. Once again, the sales representative recommended the “Magic Mushroom Chocolate Bar” from Silly Farm as a substitute. Zachary purchased two (2) “Wavy Wafer Magic Mushroom Chocolate Bars” and went home.

That evening, while preparing dinner for his fiancée, he consumed some of the chocolate bars. He had planned to skip dinner and have only a protein shake, as he was working out more frequently, reducing calories, and aiming to improve his fitness before an upcoming family trip to the Caribbean. While making dinner at home between 5:30 – 8:00 PM, Zachary consumed one full Magic Mushroom Chocolate Bar and part of a second. The product packaging lacked clear usage instructions or safety warnings. As he prepared dinner, he began experiencing mental status changes and became frightened, telling his fiancée that something was happening.

Shortly after, Zachary reportedly came downstairs naked and carrying weapons, left the home, and experienced severe memory lapses. His recollection of the evening is fragmented, but he remembers hallucinations and believing he was “Jesus,” sent to confront “Satan” at Budiman Smoke Shop. Upon information and belief, store surveillance footage should confirm he entered and shot multiple people, including an employee and a customer, killing Emad Makram Thabet Saadalla and Celcei Neil Johnson. He then left in his vehicle and shortly after police found him crashed into a side rail on a bridge. He was then taken into custody and evaluated for his psychiatric symptoms.

Toxicology Findings

Following his arrest, law enforcement and the South Carolina Law Enforcement Division (SLED) conducted forensic drug testing on used and unused chocolate bars found in his home and a blood sample obtained from Zachary. The results are consistent with a drug-induced psychotic reaction.

A comprehensive toxicology screening was performed on the blood sample from Zachary Elias (collected on 12/04/24 following the incident and his arrest) by the South Carolina Law Enforcement Division (SLED) Forensic Services Laboratory (see attached SLED toxicology report). The toxicology results detected tetrahydrocannabinol (THC, marijuana) and psilocin, the active metabolite of psilocybin mushrooms using GC/MS methodology. Tests for other common illicit and prescription drugs, including amphetamines, barbiturates, benzodiazepines, opioids, cocaine, methadone, fentanyl, and tramadol, returned negative results.

| Toxicology Results - Blood | |
|----------------------------|------------|
| Tetrahydrocannabinol (THC) | 11 ng/mL |
| Psilocin | (Positive) |
| Ethanol | (Negative) |

Multiple samples of the Magic Mushroom Chocolate Bar ("Wavy Wafer") manufactured by Silly Farms, LLC and sold to Zachary Elias on the date of the event were also tested by SLED for forensic drug analysis. The results confirmed that the commercially available product contained a prohibited Schedule I hallucinogen, psilocin. Delta-8 and Delta-9 THC were detected in a vape pen found in the home, consistent with his blood sample results and established use of CBD gummies for sleep.

| Toxicology Results – Evidence | | |
|-------------------------------|--|--|
| Item | Description | Result |
| 4 | Chocolate bar | Psilocin (C-I) |
| 31 | Silly Farms Magic Mushroom Chocolate box with residue | No analysis performed |
| 32 | Silly Farms Magic Mushroom Chocolate box containing plastic bag containing partial chocolate bar | Psilocin (C-I) |
| 34 | Purple Vape Pen Containing Wax Substance | Delta-8-THC (THC) Delta-9-THC (THC) |
| 36 | Wavy Wafer Box Containing Two Silly Farms Magic Mushroom Chocolate boxes containing plastic bag containing chocolate bar | Psilocin (C-I) |
| 37 | Wavy Wafer Box Containing Two Silly Farms Magic Mushroom Chocolate boxes containing plastic bag containing chocolate bar | Psilocin (C-I) |

The presence of psilocin in the chocolate bars confirms that the product was contaminated to include hallucinogenic compounds capable of inducing substantial altered mental states, hallucinations, and psychotic symptoms. Given that there were inadequate dosage instructions or safety warnings relevant to the undeclared illicit substance found within the product, the risk of overdose or unexpected psychoactive effects to a consumer are significantly increased.

Analysis of the Magic Mushroom Chocolate Bar ("Wavy Wafer")

Misrepresentation of Ingredients

The Magic Mushroom Chocolate Bar ("Wavy Wafer") produced by Silly Farms, LLC is marketed as containing *Amanita muscaria*, a mushroom species known for its active compound, muscimol. Muscimol acts as a GABA-A receptor agonist, producing sedative, hallucinogen, and dissociative effects.

Amanita muscaria is commonly sold as a legal psychoactive alternative to psilocybin mushrooms. The key compounds include muscimol, a GABA-A receptor agonist that induces sedation, hallucinations, dissociation, and altered cognition, and ibotenic acid, a prodrug to muscimol that extends hallucinogenic effects and causes neurotoxicity. Unlike psilocybin, muscimol functions more like a depressant than a serotonin agonist, though both are associated with producing hallucinations, paranoia, and psychosis. Despite rising concerns about safety, muscimol has not yet been classified as a federally controlled substance, though some states (e.g., Louisiana and Florida) have moved to restrict its sale.

However, forensic testing by SLED revealed that the bars actually contained psilocin, the active metabolite of psilocybin mushrooms, a Schedule I controlled substance under federal law. Additionally, Zachary's blood toxicology report confirmed the presence of psilocin, not muscimol, indicating that he unknowingly ingested a hallucinogen different from what was advertised.

History of Amanita Species, Muscimol, and Ibotenic Acid

Commercial mushroom product manufacturers often attempt to circumvent DEA and regulatory oversight by trying to avoid the use of psilocybin and psilocin by utilizing other species of hallucinogenic mushrooms named *Amanita muscaria* and *Amanita pantherine*. These mushroom species are known to produce two (2) other chemicals pharmacologically active, muscimol and ibotenic acid. Each of these chemicals produce psychoactive and hallucinogenic effects rivaling psilocybin and psilocin if enough are ingested. While *Psilocybe mexicana* and its constituents (i.e., psilocybin and psilocin) are classified as Schedule 1 controlled substances, *Amanita muscaria* and its constituents (i.e., muscimol and ibotenic acid) are illegal in Louisiana (2005) and are under critical review in other US states. Florida Department of Agriculture and Consumer Services halted sales of some amanita-based products. Contamination of products with heavy metals and other undisclosed substances places consumers at risk for poisoning and severe adverse reactions. An increase in the number of emergency room and poison control reports is heightening concerns for consumer safety.

Unlike psilocybin, which acts on serotonin receptors the brain, muscimol functions as a potent GABA-A agonist and ibotenic acid functions at the glutamate receptors, specifically at the N-methyl-D-aspartate, or NDMA, and trans-ACPD receptors sites across the brain. Modulating brain function and neurotransmitter activity in these sites produces neurotoxicity, central nervous system depression, hallucinations, sedation, and altered cognition. Historically, muscimol has been used in indigenous shamanic rituals for its mind-altering effects. Ibotenic acid is also known to be a pro-drug which is ultimately converted into muscimol, which extends the duration and intensity of psychoactive effects. These substances can cause paranoid psychosis, visual and auditory hallucinations with symptoms extending for hours to days post ingestion. Chronic use or high dose exposure to ibotenic acid is associated with excessive shifts in calcium (Ca²⁺) resulting in enhancement of the mitochondrial electron transport system and neuronal cell death.

More recently, muscimol and ibotenic acid are being utilized in the commercial market in the United States as an unregulated psychoactive substance, often marketed under misleading labels as a sleep aids or wellness products. There is an abundance of medical literature that demonstrates the psychoactive properties of these substances, but the United States Drug Enforcement Agency (DEA) has not yet formally classified muscimol or ibotenic acid as either "temporary controlled" or "controlled" substances.

DEA Scheduling Process and the Status of Muscimol

The United States Drug Enforcement Administration (DEA), in coordination with the Department of Health & Human Services (HHS) and the Food & Drug Administration (FDA), classifies substances under the Controlled Substances Act (CSA) based on their potential for medical use, risk for abuse and dependence, and overall impact on public health. This classification process includes an eight-factor scientific analysis that evaluates patterns of abuse, pharmacologic effects, and the likelihood of dependence or harm (DEA, 2023). Currently, muscimol is not classified as a controlled substance at the federal level, primarily due to limited epidemiologic data on widespread abuse, its historical use as a naturally occurring compound, and the absence of structured clinical trials assessing its addiction potential. However, the DEA has the authority to impose "temporary" or

"emergency" scheduling in response to emerging public health threats, as demonstrated by its rapid regulation of synthetic cannabinoids and designer opioids. The increasing number of muscimol-related intoxications and severe psychiatric reactions, including paranoia, hallucinations, and psychosis, has led to heightened scrutiny from medical professionals, law enforcement agencies, and regulatory bodies.

Regulatory Concerns and Consumer Safety Risks

Manufacturers of psychoactive mushroom products have developed various strategies to circumvent DEA oversight and regulatory scrutiny. One common tactic is rebranding these substances as "nutritional" or "wellness" products, avoiding direct classification as psychoactive hallucinogens. Many companies attempt to portray the utility of these products as dietary supplements, sleep aids, nootropic "brain boosters," or microdosing kits, allowing them to appeal to consumers seeking legal psychedelics while avoiding federal drug classifications. Additionally, manufacturers employ packaging and marketing techniques designed to minimize perceived risk. Amanita-based products are often packaged similarly to candy, snacks, and energy supplements, featuring bright, playful branding that may appeal to younger consumers. Unlike regulated tobacco, cannabis, prescription medications, dietary supplements, or over-the-counter pharmaceutical products, these items frequently lack standardized dosing information or clear safety warnings, leaving consumers unaware of potential risks.

| Nutritional Products |
|---|
| <ul style="list-style-type: none">• Mushrooms (i.e., whole or dehydrated)• Oils• Syrups• Powders• Seasonings |
| Commercial Recreational Edible Products |
| <ul style="list-style-type: none">• Candy• Gummies• Wafers• Chips• Chocolate bars• Vape pen solutions• Beverages (i.e., coffee, tea, fermented liquids, probiotics)• Medicinal Supplement (i.e., capsules, tablets, tinctures, and sublingual solutions) |

Another method involves substituting and mixing psychoactive compounds to enhance effects while evading detection. While many products claim to contain only muscimol, forensic analysis has revealed undisclosed substances, including psilocin and other hallucinogens. Certain forms, such as vape solutions, gummies, and infused beverages, deliver concentrated doses, heightening toxicity risks. Manufacturers also exploit state and international loopholes by distributing products online and through retail outlets in regions where muscimol is not explicitly regulated. Since it remains unclassified at the federal level, it is legally sold in many states, while some products are imported from countries with minimal oversight, making enforcement and consumer protection more difficult.

The lack of standardized consumer safety measures further exacerbates the risk associated with these products. Without clear dosing recommendations, users are susceptible to overdose and prolonged intoxication. Additionally, inconsistent labeling prevents consumers from accurately assessing product potency, and no mandated safety testing for contaminants has led to findings of heavy metals and undisclosed psychoactive drugs in laboratory analyses. The delayed onset and prolonged duration of effects also increase the likelihood of unexpected psychiatric crises. A recent study published by University of Virginia researchers (Avery Michienzi et al.) in the CDC's Morbidity and Mortality Weekly Report (MMWR, July 2024) revealed that many Amanita-based products contained psilocin, caffeine, and kratom, despite advertising only muscimol.

In addition to the psychoactive effects, ingesting products derived from *Amanita muscaria* mushroom species have been associated with poisoning and fatality. Ethan Meisel, et al., published case studies of individuals who died from complications

after ingesting muscimol and ibotenic acid (Wilderness and Environmental Medicine, 2002). These findings underscore a severe lack of transparency and regulation in the industry, highlighting the urgent need for stricter oversight and consumer protections.





Conclusion

This case involves a breach in proper safety protections (i.e., warnings, labeling, and guidance) and the distribution of an illegal psychoactive controlled substance (i.e., Schedule I - psilocin) without disclosure to the consumer. It is critical to properly convey the risks of ingestion of products derived from *Amanita muscaria* (i.e., muscimol or ibotenic acid) concerning the potential for psychiatric complications. The product label for Wavy Wafer from Silly Farms, LLC fails to provide a consumer with adequate understanding to manage dosing. The only consumer warnings available on the packaging state:

- 1) Consume slowly in a safe environment
- 2) Do not operate any motor vehicle while using this product
- 3) Keep away from children and pets

There are numerous factors that establish this case a classic example of an involuntary intoxication or unintentional insanity produced by a drug-induced psychosis. A detailed review of the facts in this case reveal that Zachary Elias had no past medical, psychiatric, or substance use disorder history. In addition, he had no criminal history or concerns with anger or behavior management, quite the contrary to be accurate. Zachary had experience with CBD gummies as a sleep aid but was misled by the staff at Budiman's Smoke Shop that the use of an Amanita-based (muscimol) product would be interchangeable as to pharmacology, therapeutic effect, and adverse side effect profile. The store employees did not have the necessary credentials or expertise to advise or make such recommendations. In addition, neither the sales representative, the product packaging, nor the Silly Farms website provided sufficient consumer guidance as to proper dosing guidelines or the risk for severe psychiatric side effects. The risk to consumers is further amplified by the manufacturing and distribution of the Wavy Wafer Mushroom Chocolate Bar that contained the undisclosed Schedule I hallucinogen psilocin.

Additionally, the Silly Farms, LLC website provides consumers with a PDF copy of a quality assurance report, performed by Interstellar Labs (shown below) which states that psilocin, psilocybin, and ibotenic acid were "not detected" and not components of their commercially available product. Based on confirmatory forensic testing completed by SLED, this is inaccurate, misleading, and dangerous to consumers.


| Customer: SILLY FARMS | EA Sample ID: F03MEL-119 Sample Name: SF Wavy Wafer Sample Type: Chocolate Batch/Lot: SFBA-EP0338 | Date Received: 2/20/2024 Date Completed: 2/20/2024 |  INTERSTELLAR LABS | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|---|--|---------------|---------------|-------------|----------------|---------------------------|----------|--------------|--------------|---|----|------------|--------------|--------------|---|----|----------|------|------|---|----|---------------|--------------|--------------|---|----|
| Summary of Results | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"><thead><tr><th>Analysis Type</th><th>Method</th><th>Date Tested</th><th>Status</th></tr></thead><tbody><tr><td>Psychoactive Constituents</td><td>HPLC</td><td>2/20/24</td><td>Complete</td></tr></tbody></table> | | | | Analysis Type | Method | Date Tested | Status | Psychoactive Constituents | HPLC | 2/20/24 | Complete | | | | | | | | | | | | | | | | | |
| Analysis Type | Method | Date Tested | Status | | | | | | | | | | | | | | | | | | | | | | | | | |
| Psychoactive Constituents | HPLC | 2/20/24 | Complete | | | | | | | | | | | | | | | | | | | | | | | | | |
| Psychoactive Constituents Analysis | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"><thead><tr><th>Analyte</th><th>Result (ug/g)</th><th>%</th><th>Specifications</th><th>LOQ (ug/g)</th></tr></thead><tbody><tr><td>Psilocin</td><td>Not Detected</td><td>Not Detected</td><td>-</td><td>10</td></tr><tr><td>Psilocybin</td><td>Not Detected</td><td>Not Detected</td><td>-</td><td>10</td></tr><tr><td>Muscimol</td><td>2.10</td><td>0.09</td><td>-</td><td>10</td></tr><tr><td>Ibotenic Acid</td><td>Not Detected</td><td>Not Detected</td><td>-</td><td>10</td></tr></tbody></table> | | | | Analyte | Result (ug/g) | % | Specifications | LOQ (ug/g) | Psilocin | Not Detected | Not Detected | - | 10 | Psilocybin | Not Detected | Not Detected | - | 10 | Muscimol | 2.10 | 0.09 | - | 10 | Ibotenic Acid | Not Detected | Not Detected | - | 10 |
| Analyte | Result (ug/g) | % | Specifications | LOQ (ug/g) | | | | | | | | | | | | | | | | | | | | | | | | |
| Psilocin | Not Detected | Not Detected | - | 10 | | | | | | | | | | | | | | | | | | | | | | | | |
| Psilocybin | Not Detected | Not Detected | - | 10 | | | | | | | | | | | | | | | | | | | | | | | | |
| Muscimol | 2.10 | 0.09 | - | 10 | | | | | | | | | | | | | | | | | | | | | | | | |
| Ibotenic Acid | Not Detected | Not Detected | - | 10 | | | | | | | | | | | | | | | | | | | | | | | | |
| NOTES: NS = NOT SPECIFIED LOD = LIMIT OF DETECTION LOQ = LIMIT OF QUANTIFICATION | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <div><div>Interstellar Labs 3770 Cherry Lane Suite 101 Westminster, CO 80031 (303) 440-1111 www.interstellarlabs.com</div><div> Lance R. Smith Laboratory Director 2024-02-20</div></div> <p><small>The sample analyzed was prepared prior to being from a closed food container, with foreign matter. The testing procedures, equipment, materials, and standards used are all in accordance with ISO 17025:2017 standards. The laboratory report is true and accurate to the sample analyzed above and may not be applied to any similar or identical products. Reports are prepared from being analyzed with a laboratory of July 2018.</small></p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Based on my education, training, and professional experience, it is my professional opinion that on the evening of December 4, 2024, that Zachary Elias experienced an unintended acute hallucinogenic mushroom-induced (i.e., psilocin) psychosis. The symptoms he exhibited, including delusional thinking, hallucinations, significant behavioral alterations, and impaired memory are consistent with the medical literature surrounding psilocin neurotoxicity. The deaths of the two individuals in this case are tragic. In addition, Zachary Elias was also an unintended victim of the fraudulent and criminal manufacturing, marketing, and sale of Wavy Wafer Chocolate bars (produced by Silly Farms, LLC and sold by Budiman's Smoke Shop). Zachary Elias was unaware of the risks associated with the product that was recommended and sold to him by these vendors due to inadequate packaging (i.e., insufficient safety warnings or instructions for use) and contamination (i.e., inadequate manufacturing processes, lack of quality control testing, and undisclosed Schedule I psychoactive substance "psilocin").

Given the increasing prevalence of products marketed as being derived from *Amanita muscaria* (muscimol and ibotenic acid), but actually containing psilocybin and psilocin heightens concerns over the inadequacies of manufacturing processes and quality control across the industry. In addition, there is a need for consumer education and enhanced product labeling to properly warn of the potential for severe psychiatric adverse side effects of each of these known psychoactive substances (i.e., muscimol, ibotenic acid, psilocin, and psilocybin).

The case of Zachary Elias exemplifies the fraudulent distribution of a Schedule I substance (psilocin), leading to unintended drug-induced psychosis and two fatalities. The Magic Mushroom Chocolate Bar, manufactured by Silly Farms and sold by Budiman's Smoke Shop, unlawfully contained psilocin, violating both federal controlled substance laws and its own labeling. Failures in customer education, product warnings, and the undisclosed presence of psilocin directly contributed to this incident. Psilocybin and psilocin are explicitly illegal in South Carolina. The sale of this product within the state was therefore unlawful, constituting a clear violation of both federal and state drug laws. Simply stated, had it not been for the illegal distribution and unintended consumption of the Wavy Wafer Mushroom Chocolate Bar, the tragic outcomes of this case would not have occurred.

Sincerely,



Dr. Daniel E. Buffington
Clinical Pharmacology & Toxicology

Attachments:

- 1) Curriculum Vitae – Dr. Daniel Buffington
- 2) SLED Toxicology Reports (01/17/25 Evidence Samples and 02/06/25 – Serum Drug Screen)